,ticker,content
0,VAR,relative strength rs rating varian medical system var climb new percentile thursday get lift look best stock buy watch keep close eye relative price strength ibd unique rs rating measure technical performance show stock price movement last week measure other stock database year market history show market biggest winner typically have higher rs rating early stage move see varian medical system continue rebound clear threshold look winning stock try simple routinevarian medical system be not currently potential buy area see stock go form base kick new price move varian medical system post earning growth latest quarterly report sale growth come varian medical system earn rank peer medical system equipment industry group cantel medical cmd iradime irmd intuitive surgical isrg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
1,VAR,varian medical system var have relative strength rs rating upgrade friday ibd proprietary rs rating identify market leadership used worst best score show stock price performance last week match other publicly trade company decade market research show market biggest winner tend have better rs rating begin new price run see ibd help make more money stocksvarian medical system be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week move average top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company earn rank peer medical system equipment industry group cantel medical cmd be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
2,VAR,rare market gyration keep crop present challenge risk model financial institution italian debt emerge market currency extreme market move be take hold raise prospect force selling portfolio adjust maintain steady level risk potential wake call trader lull successive record lows see volatility gauge threaten crimp risk adjust return unhedge portfolio thing be change say victor haghani founder chief executive elm partner management founding partner long term capital management vigilance be important here be big move italy big move isolate emerge market get newsletter deliver inbox more info product service privacy policy term probability measure used investment bank algorithmic firm be more complicate simple deviation calculation traditional value risk var model provide rough measure expect loss give day help illustrate extent investor be catch guard take surge yield year italian bond tuesday spur rome political upheaval say move fall fringe asset normal distribution curve be understatement be unprecedented kind gyration test outer edge risk management parameter used historical simulation london list ishare italy government bond etf have var confidence english mean loss be unlikely be greater give day tuesday drop meanwhile develop market have deliver more share unlikely swing turkish lira surge monday be more standard deviation outside year average daily move example investment develop nation asset have increase past few year so have likelihood var shock overseas investor accord analyst nomura holding probability such shock remain low important consider extent position foreign ownership market have grow substantially say david wagner strategist firm most recent estimate fx geographical real money allocation mexico brazil reflect high grow exposure brazilian real slump monday almost standard deviation norm not only peripheral european debt volatile emerge currency toy risk model equity market decline also look extreme tuesday european political tumult italy benchmark stock gauge fall spain main index drop move be nearly standard deviation outside year average also be interested best bond fund award used riskier styleswant invest bond issue apple other investor play high yield sector lead dow stock
3,VAR,call option make sense several top stock set report earning come week result be due defense contractor such lockheed martin lmt raytheon rtn meanwhile technology kingpin intel intc amazon com amzn microsoft msft also report many option strategy be complicate risky
4,VAR,bear haven be able put together session row so far year trend appear be intact midday thursday zigzag nasdaq be track gain thursday fall prior day advanced thursday dow jone industrial average hold gain volume stock market today fall major exchange index open higher fall european central bank president mario draghi accuse hint competitive devaluation treasury secretary steven mnuchin wednesday say weaker dollar benefit economy thursday mnuchin walk back comment part say believe freely float currency related not market then moved back positive territory breakout be more sparse thursday be wednesday still several stock show bold action early cullen frost bank cfr pop higher cross buy point flat pattern san antonio base bank report earning growth vs consensus view increase go thursday session bank sector be so far year varian medical system var rocket clear buy point flat base varian report quarterly earning growth vs estimate increase spice herb provider mccormick mkc gap heavy volume stock rise buy point company report quarterly earning rise street have expect earning rise first time jobless claim rolled vs estimate prior read be revise new home sale december come lowest estimate range consensus view be ishare home construction itb exchange trade fund dive biggest daily percentage loss nov justice department investigation nvr weaker expect result also weigh industry lead indicator december be stronger expect vs view kansa city fed manufacturing index hit vs estimate positive reading point growth rating be neutral related be gold year downtrend dow stock just trounce estimate again
5,VAR,blue chip outperformed major index thursday costliest stock price weight dow provide significant lift dow jone industrial average rise nasdaq lose add volume fall board block chance distribution day distribution day involve loss
6,VAR,thursday session be volatile early major stock index open nicely higher more weakness dollar year high euro dollar moved lows euro weaken european central bank president mario draghi hint come go rate hike improve economic condition eurozone late afternoon trading dow jone industrial average lead way rise dow jone industrial component mmm be top gainer blue chip index company report accelerate earning sale growth also increase dividend share give annualize yield boee ba also deliver solid gain nasdaq composite ease less semiconductor stock lag give back volume nyse nasdaq be tracking lower wednesday level stock market today worst performer nasdaq hailed chip sector name broadcom avgo lam research lrcx xilinx xlnx show loss range netflix nflx biogen biib outperformed nasdaq gain airline be also hard hit earning american airline aal southwest luv share american slump nearly gapping wednesday southwest drop nearly give support day move average post modest fourth quarter growth varian medical system var be standout performer strong earning soar stock gap flat base entry meaning open price be legitimate entry wednesday distribution day nasdaq lead growth stock be start show chink armor elsewhere buyer universal display oled last have reason take least partial profit straight decline heavy volume take shape thursday universal display breach day move average wednesday share be coherent cohr have also stumble recent day trade day move average share former member ibd reversed lower thursday drop fall heavy volume wednesday apple aapl extend loss give support day move average fall also give buy point earning be due feb close also ibd rv maker winnebago industry wgo thor industry tho lag loss related homebuilder stock fall lennar mortgage probe nvr earning new home salesamazon price target raise expectation strong resultsbest stock buy watch
7,VAR,stock stage strong open thursday earning news drive early trade many early leader be rapidly pare open gain dow jone industrial average jump start trade rolled higher caterpillar cat mmm give early gain follow quarterly report nasdaq composite slim open gain higher lam research lrcx xilinx xlnx biogen biib backtrack early advance dollar trade marginally lower vs euro yen day slide left year low wednesday assert strong influence day stock market action commodity moved moderately higher crude oil be fastest early mover west texas intermediate have narrow early gain less intel intc boee ba step lead dow respectively caterpillar shed early advance trade effectively flat fourth quarter result show earning comfortably expectation report wednesday overall sale growth accelerate gain quarter year high stock be look add straight week recent run end wednesday april dow industrial peer rise report board beat fourth quarter share close buy range wednesday flat base buy point apple aapl inched fang stock tech leader post early gain amazon com amzn lead pack start trade ibd stock lam research power nearly trouncing analyst earning target jump earning fiscal second quarter revenue also top expectation chip equipment maker lift third quarter earning guidance far consensus estimate lam share be trading just buy point late stage cup base xilinx edge follow fiscal third quarter report earning revenue easily clear analyst target chip developer share be just cup base buy point biogen climb cambridge mass base biotech deliver mixed fourth quarter result full year guidance be well consensus estimate gain hoist stock buy range buy point first stage base varian medical var vault nearly higher maker radiation therapy imaging system report late wednesday fiscal first quarter earning spiked revenue full year guidance also top forecast gain marked past buy point first stage flat base tal education tal spiked almost open china base chain test preparation tutor center score strong fiscal third quarter performance fourth quarter revenue guidance be consensus view surge student enrollment lift total student base tal stock have be fight retain support week move average remain buy point very late stage base economic news first time unemployment claim rise week end jan labor department say claim prior week well economist forecast application conference board index lead economic indicator new home sale number commerce department december be due et asia market come pressure hong kong hang seng index end snap day advance only index second decline past session japan tokyo nikkei dump export stock continue react week action currency europe market be generally positive paris cac lead gain afternoon trade benchmark london frankfurt strengthen gain other important early news thursday big picture market wild day tell usintel starbucks biotechs lead earning rush investing action planwhy now be best time investor look goldbiogen earning miss sale top revenue guidance bullish
8,VAR,here investing action plan thursday need know investor come day week earning frenzy hit crescendo tomorrow only handful company report be high performer boast top notch ibd composite rating include paypal pypl atlassian team winnebago wgo intuitive surgical isrg
9,VAR,consider name put watch list look stock higher rs rating varian medical system var now meet criterium increase monday proprietary rating identify market leadership show stock price action last week measure other stock major index decade market research reveal market biggest winner typically have rs rating north early stage move varian medical system be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average company top line growth fall last quarter earning share grow prior report varian medical system hold rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
10,VAR,important metric look stock be higher relative strength rating varian medical system var clear benchmark monday jump monday ibd proprietary rating identify market leadership worst best score score show stock price movement last week compare other stock database decade market research show market biggest winner often have better rs rating begin biggest climb look winning stock try simple routinevarian medical system break earlier have fall back prior entry flat base stock re watch climb buy point then fall more original entry price consider fail base best stock form new base also understand latest consolidation be later stage base make riskier establish new position add share exist take look top bottom line number varian medical system have post rise ep growth last report revenue growth have be different story come last quarter company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg fonar fonr be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
11,VAR,medtech space lead intuitive surgical isrg varian medical system var steris ste have prove be safe haven ride drug pricing fear have weigh big pharma biotech stock xanalyst say economy job number have improve allow patient finally go pseudo deferrable
12,VAR,here weekly investing action plan need know investor come week xwhat see last chance repeal replace obamacare next year midterm election be come odd success just take sharp dive meanwhile handful notable earning due
13,VAR,welcome move varian medical system var see relative strength rating rise thursday exclusive rating investor business daily track share price action worst best score score show stock price movement last week compare other stock database year market history show best stock typically have better rs rating early stage move see varian medical system continue show renew price strength hit benchmark varian medical system be not currently potential buy zone see stock go form base launch new move company top line growth fall last quarter earning share grow previous report company earn rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
14,VAR,cloud platform vendor vmware vmw see share climb month high friday company late thursday post earning comfortably beat top bottom line boost product win come least summer vmware majority own dell october announce partnership amazon com amzn amazon web service provider cloud service infrastructure vmware aw be slate release later year anticipation release be already help say vmware executive analyst alike aw partnership assure customer remain leader shift public cloud vmware coo sanjay poonen tell ibd phone interview friday public cloud company enterprise be putt most operation datum center not site datum center cloud service provider lead order aw microsoft msft azure alphabet googl ibm ibm ibd take vmware be trading average volume friday follow earning didn make ibd stock move place go find top stock be buy sell especially heavy volume maker virtualization software let server run multiple operate system thus increase flexibility lower cost vmware be longtime leader private cloud compute focus have quickly shift help company hybrid public private cloud compute environment vmware also have hybrid cloud partnership ibm have nothing now have major partnership no public cloud service likely be do more no due course poonen say vmware do have smaller partnership microsoft google company time also be rival era co opetition seldom case black white look rival potential rival say coo joined vmware almost big tech company be potential partner say microsoft be good example frenemy relationship say vmware have security product more microsoft office software service have very good partnership poonen world be move public cloud say point vmware have be build portfolio public cloud focuse product say bigger company vmware main customer not complete transition decade assume do move operation public cloud analyst be bullish aw partnership consistent recent var value add reseller survey aw partnership have prompt customer view vmware more strategic light come public hybrid cloud capability accord management have already be accelerant vmware business even vmware cloud aw service do not go live summer jason analyst william blair say research report maintain outperform rating stock strategic alliance aw have be major catalyst term customer perception be already pay dividend form strengthen term business write least investment bank hike price target vmware stock follow earning report include slight beat sale guidance slight miss ep guidance company announce share buyback program add ongoing buyback program pacific crest security analyst ben mcfadden maintain sector weight neutral rating vmware stock say share buyback be big also write research note improve result have bring optimism back story also say look sign inflection result successful datum point aw partnership become more positive share vmware stock end friday trading stock market today share have double past week sport solid ibd relative strength rating meaning stock have be top performance past year emphasis most recent month vmware also be change fiscal year coincide calendar year new year fiscal end feb guidance be year end date report fiscal result separately report result call current stub period jan feb related roundup late thursday microsoft join cisco hunt security firm
15,VAR,company provide high end highly technical equipment hospital other care provider have be something roll recently aid pronounce recovery customer spending much medical hardware industry have diversify recent string megamerger small hot group medical system maker have be get more focuse late
16,VAR,varian medical system var get mostly favorable reception wall street tuesday announce late monday spin imaging component business separate company varian say complete spinoff year end tax free distribution turn imaging unit stand alone company business be fundamentally different varian core business radiation oncology varian ceo dow wilson say statement so be better apart varian say incur charge financial guidance year be otherwise unchanged varian management say spinoff bring synergy remain company mostly increase general administrative expense couple year be offset combination cost cut service agreement company rbc capital market analyst brandon henry give thumb raise price target varian stock affirm sector perform rating varian imaging component business have weigh company topline growth last quarters henry write research note cite slow customer demand competitive pricing pressure however expect imaging component return low single digit year year growth fiscal year varian revenue growth have be stick single digit last year most recent quarter be flat henry see spinoff opportunity remain company broaden reach cancer market do not expect management like keep relatively conservative balance sheet write however expect slightly more topline growth go forward be tuck past varian stock finished trading fraction stock market today stock hold decent ibd composite rating help partly be highest rank medical group system equipment currently stand ibd ranking industry group top stock group include intuitive surgical isrg masimo masi cantel medical cmn
17,VAR,stock end slightly lower monday follow hawkish comment pair federal reserve policymaker dip dow jone industrial average nasdaq edge less volume fall nyse nasdaq compare friday accord preliminary datum stock have wobble federal reserve last week release minute april meeting suggest policymaker be lean raise interest rate early june expectation be bolster monday hawkish comment san francisco fed president john william st loui fed chief james bullard investor learn more federal reserve head janet yellen speak friday share varian medical system var edge higher post session trading company say spin imaging component business independent publicly trade company varian say spinoff expect be complete year end allow focus cancer treatment technology stock fall less regular session continue get support week move average be consolidate more year do varian medical system stack peer medical equipment industry find ibd stock checkup elsewhere stock market today lead jump more notch third straight gain german drug chemical giant bayer bayry announce plan buy agricultural seed company bayer fall more nearly meanwhile apple aapl rise more taiwan economic daily news cite supplier say receive larger expect order tech giant next generation iphone downside roper technology rop suffer biggest loss slide nearly heavy volume maker medical imaging equipment energy system wide range other product slice day day move average stock have be approach buy point cup handle base best buy bby valspar val intuit intu toll bro toll be company due report quarterly earning tuesday economic datum schedule release tuesday include new home sale april et
18,VAR,ibm ibm schlumberger slb be give lower price target tuesday valeant pharmaceutical vrx pfizer pfe be several pharma stock see analyst action ibm share close stock market today price target be lower rbc capital market maintain sector perform rating stock
19,VAR,russell sigurd varian test klystron tube palo alto calif time trumpet new stanford radio invention herald revolutionary change journalistic hyperbole more paper get right invention klystron be single most important event development microwave short radio wave tube technology write norman pond
20,VAR,stock often seem re do best fool fake perhaps never be more true fundamentally healthy stock form base base pattern base base pattern take large number form most commonly stock climb cup flat base advance less often much less then stall build cup flat base
21,VAR,result often send investor look elsewhere forget stock roar past base base buy point move new high
22,VAR,take
23,VAR,make money stock ibd founder william neil say base base pattern often form end bear market top stock be fight negative trend overall market
24,VAR,market turn launch follow day stock base base pattern be often first emerge
25,VAR,spring be hold pressure heavy object neil write
26,VAR,textbook base base pattern form low point second base just even high point lower base basis do not match way instead be more equally align be base beside base pattern produce positive breakout don have same spring load effect base top base
27,VAR,fleetcor technology flt have stumble series not quite base base pattern past year facebook fb have struggle make headway form side side flat base pattern october
28,VAR,stock be currently make good recent base base breakout include reilly automotive orly nxp semiconductor nxpi follow early january homebuilder lennar len
29,VAR,stock base base pattern construction include syke enterprise syke tableau software datum linkedin lnkd
30,VAR,remember usual healthy base rule apply term deep long buy point occur rule usually waive be requirement least uptrend prior start base
31,VAR,exceptional
32,VAR,good example base base vs trouble market be varian medical system var early november past entry point maker radiation ray therapy equipment didn have fundamental quite strong time ep be way increase then rise
33,VAR,stock form be technically base beside base pattern april october pattern be not perfect partly base form stock break nasdaq composite be collapse historical tech sell
34,VAR,nov occur volume explode average rally begin month nasdaq drop more
35,VAR,varian share rise november go gain next month stock often seem re do best fool fake perhaps never be more true fundamentally healthy stock form base base pattern base base pattern take large number form most commonly stock climb cup flat base advance less often much less then stall build cup flat base result often send investor look elsewhere forget stock roar past base base buy point move new high take twoin make money stock ibd founder william neil say base base pattern often form end bear market top stock be fight negative trend overall market market turn launch follow day stock base base pattern be often first emerge spring be hold pressure heavy object neil write textbook base base pattern form low point second base just even high point lower base basis do not match way instead be more equally align be base beside base pattern produce positive breakout don have same spring load effect base top base fleetcor technology flt have stumble series not quite base base pattern past year facebook fb have struggle make headway form side side flat base pattern october stock be currently make good recent base base breakout include reilly automotive orly nxp semiconductor nxpi follow early january homebuilder lennar len stock base base pattern construction include syke enterprise syke tableau software datum linkedin lnkd remember usual healthy base rule apply term deep long buy point occur rule usually waive be requirement least uptrend prior start base exceptional breakouta good example base base vs trouble market be varian medical system var early november past entry point maker radiation ray therapy equipment didn have fundamental quite strong time ep be way increase then rise stock form be technically base beside base pattern april october pattern be not perfect partly base form stock break nasdaq composite be collapse historical tech sell nov occur volume explode average rally begin month nasdaq drop more varian share rise november go gain next month
36,VAR,lead medical equipment stock be thursday report strong result guidance continue season theme foreign exchange headwind life science toolmaker thermo fisher scientific tmo report earning time item share year earlier quarter beating analyst consensus cent sale rise top estimate more
37,VAR,new high total stay subdue friday week range bound volatile trading bullish move market have largely be isolate tie favorable earning release recent session few highly rate stock try break friday reversed lower close apple aapl share briefly touch new high clear flat base
38,VAR,flabby year thing be shape fat bust technology developer zeltiq aesthetic zeltiq zltq offer person way get rid unwanted fat nonsurgical coolsculpt procedure selectively reduce bulge problem area used patented cool technology coolsculpt do physician office be base principle fat cell be more sensitive
39,VAR,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
40,VAR,stryker corporation syk free report second quarter result be schedule release jul market close company acquisition drive strategy be expect boost growth expand product offering segment expect company witness steady growth sale orthopaedic implant major revenue generate component be project drive second quarter earning expect improvement revenue other segment especially medsurg help company drive impressive result notably last report quarter stryker post earning beating zack consensus estimate quarter be report zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be pin indicate year year increase stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation implant implant contribute net revenue last report quarter last report quarter revenue segment be organically upside be attribute significant year year increase mako robot installation coveted mako platform also record strong performance japan south pacific canada globally stryker install mako robot be unite state zack consensus estimate orthopaedic implant quarter be report be reflect rise year year other factor playmedsurg unit drive growthmedsurg equipment product include surgical equipment surgical navigation system endoscopic communication digital imaging system well patient handle emergency medical equipment last report quarter segment account company net sale revenue segment grow constant currency cc moreover zack consensus estimate medsurg equipment revenue be peg reflect year year growth domestic international revenuesstryker be well balanced high domestic international revenue last report quarter domestic revenue account significant net sale meanwhile international sale account total revenue zack consensus estimate stryker domestic sale be pin year year same international revenue stand year year complete buyout entellus medical entellus be integrate stryker core neurotechnology spine segment enable physician conveniently perform broad range ent procedure however acquisition be expect be dilutive initially stryker adjust earning share approximately cent be likely affect top line quarter be report read more stryker close entellus buyout bolster neurotechnology line stryker be lately news make offer take massachusett base boston scientific corporation bsx free report however further term deal have be reveal stryker stryker also sign agreement acquire safeair ag swiss medical device company recently model predictsour quantitative model do not predict earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated earning esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
41,VAR,market capitalization approximately varian medical system inc var free report have be ride high revenue opportunity grow adoption proton therapy strong overseas presence emerge country however cutthroat competition niche spaceis major headwind fiscal zack consensus estimate revenue be currently peg reflect increase year year notably zack consensus estimate earning be currently peg share show increase year year stock have zack rank hold here take quick look major factor have be plague varian discuss prospect ensure term recovery varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotefactor plague varian competition be expect increase expenditure grow proton therapy market keep margin pressure further varian medical compete large electronic company withsmaller more specialize radiation therapy equipment manufacturer thus cutthroat competition niche space be likely raise company expenditure term oncology business north america be witness drop capital expenditure account uncertainty emanate health care reform anticipate change reimbursement international sale percentage revenue areincreas higher demand lower margin product china india brazil be expect keep margin pressure next several quarters hold stock apart enjoy dominant market share conventional radiotherapy believe proton therapy also hold significant promise varian medical proton therapy fall particle therapy business recently company announce installation varian medical probeam cyclotron proton beam therapy center university college hospital london nhs foundation trust uclh london england cyclotron be core piece equipment probeam proton therapy system installation be key milestone new proton therapy center varian medical probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor thereby cause lesser side effect surround tissue proton therapy system same interface used thetruebeam platform recently varian medical have upgrade probeam system software probeam version enhance site provide better image generate system integrate imager upgrade product drive company market share go forward mar varian medical announce first patient treatment st petersburg proton therapy center russia important step expand access proton therapy world key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
42,VAR,surmodic inc srdx free report be currently top performer medtech space improve price performance strong fundamental instill investor optimism stock therefore time take advantage stock price appreciation stock have rally further company share have surge industry decline year time current level be also higher index return last day zack consensus estimate narrow cent loss cent share company have zack rank buy indicate possibility outperformance term surmodic inc price consensus surmodic inc price consensus surmodic inc stock carry growth score research show stock growth score combine zack rank strong buy be better pick let find bullish trend sustain stock impressive performance long run surmodic effort improve research development stature have be key growth driver company whole product solution pipeline sirolimus base knee dcb program deserve mention here surmodic have be make progress internally develop balloon platform company have be work preclinical study datum package be used determine readiness first human clinical trial company be expect make continue progress rest fiscal company have also make significant progress development av fistula drug coat balloon drug delivery pipeline surmodic recently get fda clearance telemark support microcatheter telemark support microcatheter offer superior crossability complex coronary peripheral lesion further surmodic pristine hydrophilic coating offer best class lubricity low particulate be available only surmodic proprietary product expense second quarter fiscal be net sale year quarter company anticipate expense rise fiscal due whole product solution strategy investment advance transcend drug coater balloon human clinical trial preclinical work knee platform av fistula drug coat balloon project consider surmodic strength prospect company have long term goal generate double digit top line growth end fiscal generate ebitda margin fiscal other key picksa few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
43,VAR,medical group wmgi free report recently announce premarket approval pma fda augment injectable bone graft platform company initiate marketing product shortly unite state complete rollout process next week augment injectable be first clinically proven injectable protein therapeutic orthopaedic market already have strong foothold canadian australian market latest development medical expand augment franchise unite state follow news company announce plan update annual guidance second quarter earning call schedule august management latest development deliver sustain growth augment regenerative solution platform next several year share upshare medical inched close follow announcement fact stock have return almost compare industry rally current level also compare favorably index rise stock have zack rank hold be pma require augment injectable pma be fda process scientific regulatory review class iii medical device class iii medical device provide quick recovery present potential unreasonable risk illness injury investor notice augment injectable bone graft be class iii medical device make highly unique comparison traditional autologous bone graft allograft synthetic bone growth substitute be already available market pma approval augment injectable have provide medical competitive edge niche medtech space unite state medical augment platformnotably augment injectable bone graft platform have same clinical indication company flagship augment bone graft augment bone graft receive fda approval fact augment bone graft be first only alternative autograft hindfoot ankle arthrodesis platform be currently third year market have be fastest grow product company portfolio augment line product fall biologic revenue segment rake first quarter year level international revenue segment rise sale drop have estimate market opportunity approximately orthopaedic market key picksa few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
44,VAR,global medical device industry have demonstrated strong sustainable growth recent past banking age population increase incidence chronic lifestyle disease increase adoption artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector appear be pink health go kpmg datum medical device industry global annual sale be forecast rise more year reach nearly cision report say unite state be largest medical device market world present rake more revenue several socio political hazard economic dip medical device company have be ride high innovation increase consolidation emerge market expansion tax cut undoubtedly have be very profitable investment space late here be few major development abolition medtech tax bipartisan year suspension medical device tax impose excise tax medtech manufacturer mark temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer thus instilling investor optimism ratification tax repeal amendment have encourage massive investment sector uptrend continuesapart tax relief medtech fraternity have also be ride high ongoing merger acquisition trend space fact various report suggest have be key catalyst drive healthcare space late datum provide biospectrum asia activity medtech space surge increase value aggregate more major acquisition recent past include becton dickinson company bdx free report acquisition bard johnson johnson jnj free report buyout actelion pbm health insurer health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer basis moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script cigna ci free report come just month drug chain pharmacy giant cvs health corp cvs free report announcement acquire nation third largest health insurer aetna be important digital revolution medtechlatest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late trade war fear grip medtechthe sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector likely bear brunt trade dispute go datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade zack industry rankwithin zack industry classification medical device be broadly group medical sector zack sector further sub divide industry expand level medical instrument medical product medical dental supply medical info system rank industry zack sector base earning outlook fundamental strength constituent company zack industry rank be top zack classify industry medical info system top medical dental supply top medical instrument bottom medical product backtesting show top zack rank industry outperform bottom factor more analyze zack industry rank different medical device segment be say apart certain medical product stock term outlook aforementioned medical device subsector be overall positive price price performance major zack categorize sub industry be follow past day have gain med instrument space have rise stock space have be trading be varian medical system inc var free report steris plc ste free report edward lifescience corp ew free report medical product subsector industry rank indicated bearish tone sector have increase period player space be haemonetic corp hae free report baxter international inc bax free report boston scientific bsx free report zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
45,VAR,allscript healthcare solution mdrx free report recently partner singapore largest public healthcare group singhealth view implement ipro anesthesia ipro anesthesia be cloud base mobile anesthesia information management system aim design practice produce complete compliant legible anesthesia record multus modular platform be design fit need hospital size specialty center notably follow announcement company share have inched eventually close past year allscript share have rally outperform industry rally believe such development provide allscript competitive edge healthcare hcit space singhealth be healthcare group more clinical specialty network community hospital primary care clinic lately bid significantly expand coveted followmyhealth platform allscript acquire florida base healthgrid hold company read more allscript acquire healthgrid improve patient outcome management used apis exchange datum electronic health record ehr be good step better allscript ehr singapore base comprehensive medical care provider singhealth have earlier select allscript flagship sunrise suite solution successfully leverage company open platform application programming interface apis moreover even past hospital singapore have experience success used allscript open apis allscript sunrise allscript sunrise be fully integrate platform connect clinical financial aspect hospital health system inpatient outpatient care instance integrate health information system start used allscript open apis sunrise california base nanthealth used allscript api validate save datum directly sunrise patient record furthermore allscript eye further expansion footprint singapore ministry health later implement allscript sunrise clinical bed sengkang general community hospital system moreover last report quarter allscript announce be join force california base rideshare company lyft incorporate emergency transportation directly physician integration lyft proprietary apis allscript open platform allscript sunrise ehr enable clinician order lyft service patient market prospectsper research hcit market be expect reach cagr factor such grow need manage regulatory compliance healthcare solution government support healthcare solution rise need curtail escalate healthcare cost drive market zack rank key picksallscript currently carry zack rank hold better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
46,VAR,baxter international inc bax free report be schedule report second quarter earning jul market open expect company see steady growth back international venture majorly drive second quarter result raise guidance strategic collaboration be other tailwind last report quarter baxter post adjust earning share cent beat zack consensus estimate improve year quarter cent quarter be report zack consensus estimate revenue be peg reflect year year rise zack consensus estimate adjust earning share be peg cent indicate increase baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestrong international presence likely drive resultsbaxter have strong presence foreign market help company gain traction last report quarter company international sale account impressive total revenue baxter advanced surgery team recently launch tisseel prima europe furthermore japan company renal care team launch kaguya peritoneal dialysis technology last report quarter baxter see higher volume shipment iv solution mexico unite state company look forward reallocate additional iv solution select south america manufacturing facility management help revamp production process manufacturing facility unite state puerto rico other factor playrais guidancebaxter have raise guidance company expect sale growth constant currency cc project adjust earning share continue operation range full year zack consensus estimate be peg guide range second quarter company expect sale growth approximately cc baxter expect adjust earning continue operation cent zack consensus estimate be pin cent high end guide range strategic buyoutsbaxter have be banking strategic acquisition collaboration enhance exist product portfolio recently baxter complete acquisition preveleak mallinckrodt view boost surgical portfolio hemostat sealant notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt buyout do not prove accretive last report quarter management expect deal be modestly reward acquisition claris injectable limit baxter expect revenue worth lately baxter announce partnership international society nephrology isn spread awareness chronic kidney disease awareness therapy emerge market reflect baxter focus specialize renal care be part baxter hospital product segment have be underperform last year baxter expect sale previous guidance however guide figure be much lower model predictsour quantitative model do not predict earning beat baxter quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate have be illustrated earning esp baxter have earning esp uncover best stock buy sell re report earning esp filter zack rank baxter carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock carry zack rank becton dickinson company bdx free report have earning esp stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
47,VAR,varian medical system inc var free report be schedule report third quarter fiscal earning jul market close favorable revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence be likely drive company earning be report quarter last report quarter company adjust earning come share surpass zack consensus estimate metric also improve year year basis revenue outpaced zack consensus estimate currently zack consensus estimate third quarter revenue stand reflect rise same adjust earning be peg penny share mirror decline let delve deeper find factor be likely impact varian medical upcoming quarterly result varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quoteoncology boost growthwe be upbeat varian medical oncology business account company total revenue second quarter say quarter oncology revenue totale cc year year basis notably varian medical solid performance oncology business margin expansion launch halcyon radiotherapy treatment system have be key highlight fiscal third quarter moreover company have be address tier mid tier market edge truebeam vitalbeam product winning international contract oncology space varian medical also inked aud deal acquire sirtex australian base company be focuse interventional oncology therapy latest agreement expand varian medical addressable market interventional oncology management varian medical leverage capability treatment plan delivery image guidance process oncology practice management software radiation safety unit sirtex interventional oncology platform expect buyout be accretive company third quarter result varian oncology care management platform varian medicalacquired evinance innovation small privately hold montreal base company specialize clinical decision support software earlier year streak other favorable developmentson jun varian medical announce installation varian probeam cyclotron proton beam therapy center university college hospital london nhs foundation trust london fact california base provider cancer care have already start consolidate global foothold provide proton therapy solution read more varian medical probeam platform gain foothold uk latest move be boost company third quarter bottom line performance varian medical announce software technology training education cooperation agreement brazil ministry health moh university science technology institution ict brazil enable company increase customer base brazil latin america read more varian medical merge brazil moh fight cancer meanwhile korea varian medical flagship hyperarc high definition radiotherapy hdrt be used treat patient brain cancer hyperarc be high definition radiotherapy technology provide intracranial radiosurgery solution capitalize unique capability varian medical truebeam edge treatment system be support company eclipse treatment plan software apr varian medical have sign agreement stockholm city council provide equipment related service radiation therapy department new karolinska solna nks hospital stockholm sweden truebeam radiotherapy system advanced cancer treatment earning whispersper proven model stock need have positive earning esp zack rank strong buy buy hold deliver positive earning surprise fiscal third quarter be case here see zack esp varian medical have earning esp uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter corp abc free report have earning esp zack rank see complete list today zack rank stock here bio rad laboratory bio free report have earning esp zack rank davita inc dva free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
48,VAR,medical device industry trend be reflective extensive discovery innovation life science industry past few year study publish cnbc medical device company have gain importance healthcare world improve research development technology far reach innovation gene therapy newer drug combination patient monitoring help big datum year shape medical fraternity unite state tax suspension fuel medical device market have further gain momentum owing recent year suspension controversial medical device tax excise tax be implement part obamacare medtech manufacturer significantly restrict activity accord article publish xtalk medical device tax be responsible reduction spending decline overall sale however be be see tax be fully eliminate resume year period now deferral encourage activity space bode well medtech company notably past month medical instrument industry have rally index return lead revolution medtechthe medtech space currently offer unprecedented opportunity growth market share expansion solid investment have help manufacturer use benefit big datum artificial intelligence ai medical mechatronic industry be also catch digital datum age enormous size datum be capture technology arrive business insight help healthcare sector provide better care reduce wastage latest trend adopt electronic health record ehr service medtech space have also be gain popularity major hcit healthcare bigwig have carved niche big datum domain be cerner corporation athenahealth inc company be make significant investment boost ehr platform meanwhile medical mechatronic be much await digital evolution global healthcare industry provide innovation healthcare industry reduction size age old medical device development low cost disposable device engineering concern einfochip believe mechatronic be future medical device benefit mechatronic have be see form printing cancer study development better medication deadly disease notably intuitive surgical isrg free report minimally invasive da vinci surgical system stryker corporation syk free report robotic arm assist surgery platform mako deserve mention here choose winning stocksgiven favorable scenario investment medical device stock strong potential seem be wise choice stock strong fundamental solid prospect make reward addition portfolio have take help zack stock screener select favorable stock shortlist stock vast universe medical product have picked one zack rank strong buy buy growth score notably growth score be comprehensive tool come handy screening winning stock broader sector research show stock growth score combine zack rank outperform most stock see complete list today zack rank stock here abiom inc abmd free report sport zack rank stock growth score be indicate outperformance term be underpin fact stock have impressive long term earning growth last day zack consensus estimate abiom current quarter earning share have increase cent abiom inc price consensus abiom inc price consensus abiom inc quotein past month share abiom have sky-rocket industry decline abiom flagship impella world smallest heart pump have continue be growth driver notably fourth quarter fiscal company spend year quarter integer holding corporation itgr free report carry zack rank have growth score long term earning growth be project last day zack consensus estimate integer hold current year earning share have increase integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quotein past month share integer holding have rally fare better industry integer holding have also be enhance profitability area advanced surgical orthopedic power solution focuse sale growth cost structure initiative company plan invest more area cardio vascular neuromodulation accelerate sale market penetration notably first quarter company spend year year basis varian medical system var free report stock have zack rank growth score company long term earning growth be project last day zack consensus estimate varian medical current year earning share have rise varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotein past month share varian medical have rally significantly beating industry varian medical ride solid growth prospect coveted halcyon radiotherapy treatment system hyperarc platform halcyon be design offer cost effective cancer care hyperarc be high definition radiotherapy technology second quarter fiscal company spend prior year quarter steris plc ste free report have zack rank growth score company current year earning growth be project last day zack consensus estimate steris fiscal earning share have increase steris plc price consensus steris plc price consensus steris plc quotein past month share company have rally considerably better industry company goal be provide infection prevention other procedural product service fourth quarter fiscal company invest year year basis idexx laboratory idxx free report carry zack rank growth score company long term earning growth be project last day zack consensus estimate idexx current year earning share have increase idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotein past month stock have rally significantly outperform industry company develop manufacture distribute product primarily companion animal veterinary livestock poultry first quarter company spend significant year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
49,VAR,varian medical var free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock past year varian medical share have rally versus industry decline current level be also better index gain last day zack consensus estimate current year earning have improve share california base provider radiotherapy solution carry zack rank buy indicate possibility outperformance term furthermore stock have growth score research show stock growth score combine zack rank strong buy be better pick most let find bullish trend sustain stock impressive performance long run make attractive pickdiverse product portfoliovarian medical boast highly diverse product spectrum have secure solid customer base year halcyon radiotherapy treatment system hyperarc platform deserve special mention regard notably halcyon platform have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt meanwhile hyperarc be high definition radiotherapy technology design treat multiple metastase brain cancer case furthermore varian medical recently announce plan demonstrate comprehensive portfolio advanced brachytherapy solution be expect boost company oncology system segment read more varian demonstrate brachytherapy solution portfolio strong international presencevarian medical foresee substantial opportunity cancer care emerge market company have expand reach strategic overseas buyout varian medical sign agreement acquire sirtex australian base company focuse interventional oncology therapy additionally cooperative cl enterprise lead distributor radiotherapy equipment taiwan have be acquire varian medical moreover varian medical recently announce software technology training education cooperation agreement brazil ministry health moh bid make quality radiotherapy treatment readily accessible latin america read more varian medical merge brazil moh fight cancer solid guidancevarian medical provide solid guidance fiscal revenue growth be expect range year year basis fiscal zack consensus estimate revenue be peg adjust earning share be project range zack consensus estimate same be pin guide range other key picksa few other top rank medical stock be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank abiom have project long term earning growth rate stock hold zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
50,VAR,jun issue update research report steris plc ste free report company have be actively try expand adjacent market strengthen core business acquisition dilution however company operate tough competitive landscape be concern stock carry zack rank buy share developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have outperformed industry past month stock have rally industry decline be encourage steris witness favorable underlie market trend new product service offering company strong organic growth specialty service life science apply sterilization segment also buoy optimism further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change expect better align operation recent past steris have be pursue growth footprint adjacent market acquisition dilution follow synergy health buyout company sell synergy health healthcare consumable solution hcs business vernacare november hcs business used generate roughly annual revenue apart company make consolidation fiscal transaction company aim strengthen healthcare product healthcare specialty service apply sterilization technology business believe steris chase back back acquisition long run order widen business customer base courtesy solid financial position meanwhile steris compete pharmaceutical research industrial customer several large company extensive product portfolio global reach well small entity limit product offering operation few country company worry face fierce competition new infection prevention sterile process contamination control surgical support product service enter market hamper steris growth considerably moreover multiple steris client be undergo consolidation partly due healthcare cost reduction measure initiate competitive pressure well legislator regulator third party payor think company fail check customer consolidation rate now adversely impact business well financial condition other key picksa few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report varian medical system inc var free report intuitive surgical illumina sport zack rank strong buy varian medical carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth varian medical expect earning growth rate be peg current year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
51,VAR,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
52,VAR,amedisys inc am free report recently purchase back half kkr co holding common share more specifically company buy back more common stock global investment firm total transaction value deal also include aggregate outstanding share company common stock repurchase deal reflect price be yesterday close value transaction be immediately accretive company bottom line follow news share amedisys inched close trading monday jun amedisys be expect finance deal used available cash exist revolve credit facility company be left cash hand outstanding borrowing credit facility turn result net leverage ratio approximately home health hospice care provider amedisys be upbeat recent development remain line strategy deploy capital accretive manner maintain low leverage substantial borrow capacity future investment regard amedisys accretive acquisition continue be first priority capital deployment accordingly company consider transaction best utility capital give current buyout multiple company business prospect company also note kkr continue remain significant shareholder amedisys accordingly nathaniel zilkha member general partner kkr co still remain director amedisys board other recent acquisition amedisysover past year company make number strategic acquisition recent be east tennessee personal care service etpcs personal care provider headquarter knoxville tn amedisys buyout enlarge company personal care footprint outside massachusett florida apart company buy intercity home care personal care provider base malden notably intercity home care entire asset base have be take associate home care amedisys believe have wider presence massachusett other important acquisition late include home health center illinois massachusett texas hospice care center arizona massachusett tenet healthcare asset home staff earlier february last year share price performanceover past month share amedisys have outperformed industry belong stock have rally compare industry rise zack rank other key picksamedisys currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report varian medical system inc var free report intuitive surgical illumina sport zack rank strong buy varian medical carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth varian medical have expect earning growth rate current year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
53,VAR,stryker corporation syk free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock therefore time advantage stock price appreciation past year stryker share have rally significantly outperform industry growth last day zack consensus estimate earning share rise company have zack rank buy indicate possibility outperformance term let find bullish trend sustain stock impressive performance long run make attractive pick focus inorganic growthstryker have be leverage bolt buyout drive inorganic growth stryker recently acquire entellus medical inc stryker also acquire vexim recent past specialize development sale vertebral compression fracture solution company close buyout novadaq net purchase price last report quarter buyout have proven accretive stryker mako propel growthmako be stryker robotic arm assist surgery platform first quarter see strong show mako total knee platform management primary growth driver include continue demand mako tka knee platform print product foot ankle portfolio report quarter company install total robot globally unite state reflect increase year year guidance solidbuoy stellar first quarter stryker expect second quarter earning share notably zack consensus estimate earning be peg be give range moreover organic net sale growth be expect adjust net earning diluted share range management be also confident basis point improvement operate margin other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
54,VAR,bid make quality radiotherapy treatment readily accessible varian medical system inc var free report recently announce software technology training education cooperation agreement brazil ministry health moh university science technology institution ict brazil enable company fight cancer treatment brazil latin america follow announcement varian medical share price inched close be likely provide further cushion company share have gain compare industry decline year time participate ict be select varian medical basis criterium candidate interview history successful project project management expertise propose team member experience company global engineering team switzerland finland unite state train researcher select ict june california base provider radiotherapy proton therapy thus be able fortify international position expand knowledge radiation therapy technology software meanwhile korea varian medical flagship hyperarc high definition radiotherapy hdrt be used treat patient brain cancer hyperarc be high definition radiotherapy technology provide intracranial radiosurgery solution capitalize unique capability varian medical truebeam edge treatment system be support company eclipse treatment plan software varian medical radiotherapy magnatevarian medical have make noteworthy progress radiotherapy niche notably company halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide coveted hyperarc platform be design treat multiple metastase brain cancer case continue witness strong demand last report quarter halcyon platform witness total order majority greenfield site inception halcyon have see more order emerge market furthermore europe middle east india africa geography company revenue grow constant currency respectively market prospectsper research market market global radiotherapy market be project reach cagr market be expand healthy pace account grow number cancer case rise sophistication novel treatment procedure zack rank other key picksvarian medical currently carry zack rank buy other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
55,VAR,issue update research report thermo fisher scientific inc tmo free report banking several takeover include patheon fei acquisition lead scientific instrument maker be rapidly ramp inorganic growth profile company strong focus emerge market be also encourage stock have zack rank hold thermo fisher end first quarter promising note adjust earning revenue surpass zack consensus estimate be also impressed company solid international performance back strong growth emerge market china south korea india thermo fisher scientific inc price thermo fisher scientific inc price thermo fisher scientific inc quote also series product launch major progress precision medicine initiative aid thermo fisher performance moreover patheon buyout have substantially add impetus company value proposition biopharma customer notably integration have already start prove accretive thermo fisher laboratory product service segment past year thermo fisher have successfully outperformed industry stock have rally versus industry decline promising guidance also uplift mood indicate stock continuous bull run remainder year flip side company business segment have be impact unfavorable business mix past few quarters also competitive headwind rise operate cost persistently threat apart thermo fisher derive majority revenue international market expose currency volatility zack rank other key picksthermo fisher currently carry zack rank buy other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate zack rank varian medical have project long term growth rate stock hold zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
56,VAR,unite state boast be biggest medtech market date be highly regard innovation technologically advanced product world kaloroma information article validate country dominance field thank more revenue generate world medical device tax medical device industry be boom possibility courtesy year suspension infamous medical device tax lift tax make scope solid research development be likely benefit company long run excise tax be implement obamacare significantly affect advanced medical technology association lobbying group tax impair medical innovation great extent result loss lower job creation address problem senate place temporary suspension taxe january december period taxe be impose again jan only be suspend jan year device tax suspension be very few amendment see landslide bipartisan house jan medical product industry have rally significantly outperform index decline account political cultural legal trouble plague market worldwide make right backdrop few medical device stock be well position strong fundamental solid prospect have used zack stock screener pick such stock have also take care include stock zack rank strong buy buy growth score research show stock growth score combine zack rank be better pick most intuitive surgical inc isrg free report have growth score past month share intuitive surgical have gain outperform industry decline california base company zack rank recently announce be commence direct operation india distributor vattikuti technology pvt ltd moreover company flagship da vinci sp surgical system urologic surgical procedure be recently approve fda last day zack consensus estimate intuitive surgical earning share rise abiom inc abmd free report have zack rank growth score see see complete list today zack rank stock here past month share abiom have gain outperform industry decline massachusett base company recently replace wyndham worldwide corp list last day zack consensus estimate abiom earning share rise cent varian medical system inc var free report have zack rank growth score past month share varian medical have rally fare better industry fall california base provider radiotherapy solution have late be target expansion africa company coveted halcyon system have be adopt different cancer center northern southern africa furthermore varian medical recently sign software technology training education cooperation agreement brazil ministry health moh university science technology institution ict brazil last day zack consensus estimate varian medical earning share remain stable surmodic inc srdx free report have zack rank growth score past month share surmodic have gain outperform industry growth minnesota base provider medical device recently sign agreement embolitech acquire innovative thrombectomy platform technology related intellectual property broad potential peripheral vascular application enhance company focus develop highly differentiate whole product solution more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
57,VAR,baxter international inc bax free report recently announce fda approval spectrum iq infusion system dose iq safety software order simplify emr electronic medical record administration patient illinois base global medical technology company have partner first databank fdb integrate fdb infusion knowledge evidence base library iv medication dose iq safety software meanwhile baxter exist infusion system sigma spectrum platform have achieve average drug library compliance first day implementation management year unite state be estimate preventable harmful medication error associate injectable medication notably latest development strengthen baxter foothold help protect high risk infusion thereby ensure patient safety spectrum spectrum iq be first system design directional emr integration ascertain precise medication patient system work spectrum infusion pump technology important step make infusion safer be only infusion pump feature line check notification technology give visual notification match infusion pump medication be infuse furthermore system come build dose rate change error prevention feature help clinician protect high risk infusion apart patient system help clinician embed screen barcode technology provide scan prompt help maintain increase auto programming compliance automatically document infusion datum emr moreover system lead cost saving iv intravenous tubing set reduction iv tubing usage market prospectsper study market market healthcare hcit market be expect reach cagr primary growth driver market be high return investment hcit solution government directive need curtail escalate healthcare cost hence be conclude baxter move have be timely strategic price performancein past year baxter share have rally compare industry return zack rank key picksbaxter carry zack rank buy other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate current quarter stock sport zack rank varian medical have project long term growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
58,VAR,fresenius medical care fms free report post adjust earning cent american depositary share ad first quarter miss zack consensus estimate earning ad decline year year basis quarter review revenue inched year year miss zack consensus estimate constant currency cc revenue decline year year revenue first quarter witness negative impact result foreign currency translation stock have zack rank strong sell fresenius medical have outperformed industry past year company share have return compare favorably industry decline fresenius medical care price consensus ep surprise fresenius medical care price consensus ep surprise fresenius medical care quotesegmental detailshealth care service revenue decline cc year year basis segment witness organic growth year year health care product revenue increase cc organically dialysis treatment increase quarter review courtesy strong contribution same market treatment synergy acquisition geographical growthnorth america revenuesby geography north america revenue decline cc year year basis account total revenue health care product revenue inched cc higher sale renal pharmaceutical peritoneal dialysis product hemodialysis solution concentrate however be partially offset lower sale machine dialyzer end quarter company treat patient clinic north america year year be fuel higher dialysis treatment increase revenue treatment dialysis care business grow cc year year basis region meanwhile care coordination segment decline cc drive shift calcimimetic drug clinical environment unfavorable foreign exchange rate partially offset solid growth region emea revenuesrevenue region increase year year basis cc health care service health care product revenue emea segment increase cc year year basis dialysis product revenue grow cc courtesy higher sale product acute care treatment machine peritoneal dialysis product renal pharmaceutical health care service segment be primarily drive growth same market treatment however same be partially offset decline organic revenue treatment growth dialysis product revenue region be boost higher sale product acute care product peritoneal dialysis machine however be partially offset lower sale dialyzer end quarter company have patient be treat clinic emea region year year dialysis treatment increase year year basis region asia pacific revenuesrevenue asia pacific grow cc year year basis net health care service unit increase cc health care service segment asia pacific region be support acquisition cura group australia meanwhile health care product business increase cc year year basis growth segment be mainly drive higher sale chronic hemodialysis product product acute care treatment dialysis treatment region grow region latin america revenuesrevenue region increase cc year year basis notably health care product increase year year company treat patient clinic latin america year year dialysis treatment increase region solid sale machine well disposable dialysis treatment drive revenue latin america margin profit decline report quarter cc percentage revenue gross margin decline basis point bps revenue quarter fresenius medical estimate revenue growth band cc lower previous guidance cc zack consensus estimate revenue be currently peg reflect rise year year net income attributable shareholder be likely increase medical exit first quarter dull note miss zack consensus estimate count dull performance north america have be major dampener company continue face significant foreign exchange headwind further higher cost related dialysis service peritoneal dialysis product business china be likely put margin pressure fresenius medical face highly regulate environment almost country operate company have fulfill specific legal requirement include tough antitrust regulation company reconfirm mid term outlook growth strategy aim boost revenue corresponding average annual growth rate strong performance health care product segment hold promise wide range dialysis product be major catalyst company earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
59,VAR,share pra health science inc prah free report have inched release first quarter result apr upside be attribute better expect earning share ep first quarter past month stock have gain outperform industry rise let delve major factor lead uptick share maintain streak positive earning surprise company post adjust ep cent surpass zack consensus estimate penny earning surge prior year quarter tally notably company have unfavorable impact fluctuation foreign currency exchange rate quarter pra health register revenue first quarter report quarter company adopt new asc accounting standard calculate revenue used modify retrospective method accordingly metric be zack consensus estimate revenue be peg revenue improve constant currency cc year year detailsegmental company be manage reportable segment clinical research segment datum solution clinical research segment report revenue first quarter segment company receive contract customer provide clinical research service payment base fix fee fee service arrangement revenue datum solution segment amount first quarter company provide weekly monthly quarterly datum report analytic customer geographic detailstotal revenue americas come be net report revenue net revenue europe africa asia pacific come constitute net report revenue direct costsdirect cost be quarter year year total direct cost increase year year cc clinical research segment direct cost consist primarily labor related charge notably labor related cost increase segment datum solution segment direct cost consist primarily datum cost segment witness incremental direct cost year year margin trendgross profit report quarter rake prior year quarter tally gross margin come contract basis point bps net income operation increase pra health science inc price consensus pra health science inc price consensus pra health science inc health reiterate service revenue guidance range zack consensus estimate be currently peg lie guidance adjust earning diluted share be expect share zack consensus estimate be currently peg be guidance zack rank key pickspra health have zack rank hold few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
60,VAR,perkinelmer inc pki free report be currently top perform stock medtech space improve price performance strong fundamental instill confidence investor therefore haven take advantage stock price appreciation yet time add portfolio company have perform impressively first quarter be likely sustain momentum upcoming period past year share perkinelmer have rally significantly outperform industry growth just past day zack consensus estimate earning share rise cent company have zack rank buy indicate possibility outperformance term let find recent positive trend sustain stock impressive performance long run make attractive pick solid exit first quarter solid note earning cent share surpass zack consensus estimate revenue inched core discovery analytical solution da segment revenue totale quarter year year organic revenue increase year year revenue diagnostic segment gross reflect year year increase also show improvement organically raise perkinelmer expect adjust earning share be significantly higher previously issue guidance company project revenue earlier issue range unfavorable foreign exchange environment act deterrent quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion broad spectrum deliver comprehensive suite scientific informatic software solution aggregate datum actionable insight automate scalable way company product consist industry lead chemdraw software electronic lab notebook include cloud base element saas offer enterprise notebook solution tibco spotfire platform scientific datum analytic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
61,VAR,davita inc dva free report report first quarter adjust operate earning share beating zack consensus estimate cent earning increase year year basis total revenue increase year year miss zack consensus estimate davita carry zack rank hold business detailsnet dialysis related lab patient service revenue first quarter be year year other revenue be year year basis davita see impressive result kidney care business net consolidated revenue segment be year year adjust kidney care operate income be year year operate division davita davita kidney care focus set worldwide standard clinical social operational practice kidney care adjust dialysis related lab service operate income first quarter be dialysis treatment first quarter be treatment day represent increase year year davita inc price consensus ep surprise davita inc price consensus ep surprise davita inc quote company patient care cost be approximately cent treatment compare last report quarter investor notice company major segment davita medical group dmg be track divestment optum subsidiary unitedhealth group inc transaction be subject regulatory approval other customary close condition result dmg business operation have be report discontinue quarter review share repurchase updatedure first quarter davita repurchase total share approximately average price share davita have repurchase share year date basis represent nearly company total share outstanding also include approximately stock repurchase guidancedavita reiterate guidance company project kidney care consolidated operate income range operate cash flow continue operation be estimate range effective tax rate be expect range end first quarter mixed note adjust earning beating zack consensus estimate revenue miss same company see impressive result kidney care business lately operate division davita davita kidney care focus clinical social operational practice worldwide company effort control expense hold promise compelling inorganic growth story be positive flip side sluggishness other business be major headwind davita company be face adverse effect pricing pressure medical industry rise medicare insurance cost company major segment davita medical group have be track divestment optum subsidiary unitedhealth group inc further high debt level adverse effect healthcare reform increase medicare advantage beneficiary be concern earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
62,VAR,surmodic inc srdx free report report adjust earning cent share second quarter fiscal year year zack consensus estimate be loss penny revenue quarter increase beating zack consensus estimate stock have zack rank buy surmodic have outperformed industry year time stock have return compare industry rise return be also higher index return segmental report revenue segment medical device diagnostic ivd medical devicein report quarter sale improve due lower hydrophilic royalty revenue notably royalty license fee revenue totale year quarter uptick royalty license fee revenue reflect surmodic strength hydrophilic coating royalty further company gain license fee income recently announce collaboration abbott medical device product sale rise report quarter solid medical device sale medical device customer research development revenue decline year year basis unit generate operate income second quarter fiscal compare operate income year quarter ivdin quarter review sale increase upside come back strong growth stabilization biofx microarray antigen product sale operate income segment be report quarter compare second quarter fiscal surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quotemargin detailsproduct gross margin contract basis point bps second quarter product sale compare year period margin quarter suffer expense irish facility infrastructure lower medical device product gross margin second quarter fiscal expense be net sale higher net sale year quarter sg expense second quarter fiscal be revenue bps higher year year raise guidance fiscal surmodic expect fiscal revenue range previous band company expect fiscal earning share negative cent cent compare previous estimate negative cent cent zack conensus estimate be currently peg loss cent share exit second quarter fiscal solid note beating zack consensus estimate count further solid performance diagnostic segment gain strong growth stabilization biofx microarray antigen product sale hold promise surmodic issue solid guidance fiscal company solid initiative strengthen research development program bode well flip side company witness significantly high operate loss product sale decline due shipment issue particularly medical device segment further foreign exchange wo related creagh medical buyout have be major dampener surmodic drug coat balloon face stiff competition niche space company margin be expect stay pressure thank expense irish facility infrastructure lower medical device product gross margin earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
63,VAR,instituto mexicano del seguro social imss have select varian medical system inc var free report equip treatment center mexico modern radiotherapy treatment system include edge system image guide stereotactic radiosurgery varian eymsa provide edge system vitalbeam system varian provide full suite treatment plan oncology information manage cancer patient site notably eymsa be varian long standing distributor mexico company new edge radiosurgery system allow physician treat tumor noninvasively outside body carefully shape high energy ray vitalbeam system offer high quality high throughput radiation therapy low cost enable treatment center expand clinical capability serve more patient development oncologyvarian be strive boost oncology segment last quarter oncology revenue increase year year basis regard varian recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company company initiate first education workshop radiotherapy practitioner algerium recently company announce first cancer patient be treat used hyperarc high definition radiotherapy hdrt new type radiosurgery treatment sacro cuore don calabrium cancer care center negrar verona italy fourth quarter revenue inched cer segment late company have be focuse expansion brazil recently varian announce receipt anvisa registration halcyon system brazil company have announce plan open new facility jundiai brazil indicate long term commitment partnership brazilian ministry health facility have be fully equip provide varian trilogy linear accelerator hand training physician market prospectsaccord report market market global radiotherapy market be project reach worth cagr consider bountiful opportunity niche space believe company latest development be strategic fit such prospect varian latest development oncology segment buoy optimism be also line company effort establish premier cancer care provider share price estimate revision trendover past month varian share have outperformed industry term price stock have return compare favorably industry rally just current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate have rise share zack rank other key picksvarian carry zack rank buy few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
64,VAR,mar issue update research report varian medical system inc var free report company have deliver strong performance drive solid product line slow capital spending be likely mar prospect stock currently carry zack rank hold varian medical see significant product launch form halcyon therapy system company unveil halcyon radiotherapy treatment system recently inception first quarter fiscal halcyon platform witness total order receive clearance ce mark european directive allow company start selling system unite state apart radiotherapy varian medical also hold significant promise proton therapy market company probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor consequently reduce side effect surround tissue recent past varian medical have upgrade probeam system software probeam version moreover first quarter fiscal company book new proton order probeam compact single room system also have strong overseas presence company sale europe africa particularly asia be grow faster rate domestic market december varian medical announce peter maccallum cancer center melbourne australia select company eclipse treatment plan replace exist system site past year varian have outperformed industry stock have return compare industry rally varian medical system inc price varian medical system inc price varian medical system inc quotehowever due stiff competition varian medical research development expense be expect increase be likely keep margin pressure international sale percentage revenue be increase higher demand lower margin product china india brazil be anticipate keep margin strained next several quarters varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer elekta accuray such intense competition be also likely slow company expenditure term increase expenditure nascent proton therapy market zack rank key picksa few better rank medical stock be bio rad laboratory inc bio free report centene corporation cnc free report mednax inc md free report stock sport zack rank strong buy see complete list today zack rank stock here bio rad have project growth rate long term stock have return past month centene have anticipate long term growth rate stock have return past month mednax have expect long term growth rate stock have return past month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
65,VAR,masimo corporation masi free report report adjust earning cent share first quarter outperform zack consensus estimate cent bottom line improve year quarter figure cent stock have zack rank buy revenue improve year quarter beat zack consensus estimate segmental analysisproduct revenue product revenue deliver strong quarter double digit growth product revenue be quarter year year product revenue also witness impressive growth overseas market new product include nomoline capnography rainbow noninvasive blood constituent monitoring sedline brain function monitoring organ oximetry contribute result company worldwide direct product revenue total product revenue increase first quarter oem sale total product revenue increase first quarter notably january masimo receive ce mark rd rainbow lite set sensor enable use oxygen reserve index rpvi management be improve rainbow base version pvi be less costly rainbow sensor masimo corporation price consensus ep surprise masimo corporation price consensus ep surprise masimo corporation quote royalty other revenuesfirst quarter royalty other revenue fall prior year quarter margin analysistotal gross profit first quarter be year year gross margin be net revenue basis point bps year year product gross margin expand bps net revenue revenue be estimate previous projection zack consensus estimate revenue be peg significantly lower guide figure total product revenue be estimate previously issue guidance royalty other revenue be estimate adjust earning share be expect previous guidance zack consensus estimate adjust earning significantly lower guide estimate exit first quarter strong note beating consensus mark count solid guidance raise investor optimism stock company have be gain strong segmental revenue improve product revenue margin expand product portfolio wider adoption invasive patient monitoring technology be major catalyst masimo set pulse oximetry business represent considerable growth opportunity international market moreover masimo receive noteworthy ce fda clearance quarter include clearance domestic use new rad telehealth monitor way audio video capability flip side lackluster performance royalty other revenue unit be concern furthermore company face fierce competition oem distributor medical device bigwig mar top line long haul earning medtech major glancea few other top rank stock broader medical space report solid earning season be intuitive surgical inc isrg free report varian medical system inc var free report baxter international inc bax free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
66,VAR,dexcom inc dxcm free report report loss cent share first quarter line zack consensus estimate also figure be narrower loss cent report year quarter stock have zack rank hold total revenue grow year quarter revenue surpass zack consensus estimate segmental detailssensor revenue other revenue total revenue grow year year basis transmitter revenue increase prior year quarter tally receiver revenue grow year year dexcom inc price consensus ep surprise dexcom inc price consensus ep surprise dexcom inc detailsdexcom generate gross margin percentage revenue contract basis point bps year year margin be pressure due inventory change shift ous medicare international business display continue growth quarter year year basis research development expense totale quarter year year selling general administrative expense totale report quarter increase year year guidancedexcom raise full year guidance company expect revenue range previous range meanwhile zack consensus estimate revenue be currently peg be significantly lower guide estimate gross profit margin be project band report operate expense exclude investment intensive program be expect increase first quarter adjust earning meet zack consensus estimate solid contribution sensor revenue transmitter revenue receiver revenue be key catalyst moment glucose monitoring market represent significant commercial opportunity dexcom dexcom opportunity alternative market such intensive diabetes management space hospital gestational pre diabetes obesity be likely provide company competitive edge medtech space further company next generation fully disposable cgm system be also progresson flip side cutthroat competition market blood glucose monitoring device be headwind dexcom moment believe company margin continue be pressure come quarters owing high product development cost rise expenditure research development lower expect margin transmitter sale be also cause concern earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
67,VAR,share bio rad laboratory inc bio free report have gain release first quarter result upside be attribute better expect earning share ep revenue growth product line strong performance geography past month stock have gain outperform industry rise let delve factor company post adjust ep surpass zack consensus estimate earning surge prior year quarter tally revenue detailrevenue first quarter totale outpace zack consensus estimate revenue improve year quarter figure rise constant currency cc management total figure include approximately record sale associate settlement royalty dispute diagnostic segment also comprise raindance sale sale record prior year quarter geographically sale quarter grow primarily north america china asia pacific marginally offset sluggish sale europe bio rad laboratory inc price consensus ep surprise bio rad laboratory inc price consensus ep surprise bio rad laboratory inc quotesegmental analysissale life science segment post first quarter sale year year segment revenue climb cc management upside reflect growth sale droplet digital pcr process chromatography cell biology product line geographic basis sale be particularly strong north america china europe cc net sale clinical diagnostic first quarter be year year basis cc upside indicate growth immunology diabetes quality control product line geographically sale rise north america asia pacific marginsgross profit report quarter rake prior year quarter tally gross margin come contract basis point bps operate income gross significantly operate margin come expand bps full year company project revenue growth approximately cc full year gross margin be expect operate margin be project conclusionbio rad deliver stellar first quarter result earning revenue surpass consensus mark clinical diagnostic segment deliver impressive sale strong growth life science segment also hold promise company also witness growth diabetes autoimmune product line meanwhile solid growth geography north america china asia pacific indicate company strong international foothold improvement operate income margin be major positive however decline gross profit be concern company witness softness europe first quarter zack rank key picksbio rad currently carry zack rank hold better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
68,VAR,maintain streak positive earning surprise corporation abc free report post adjust earning share second quarter fiscal beating zack consensus estimate improve year year upside be attribute strong growth pharmaceutical distribution segment world courier business revenue improve almost report quarter figure surpass zack consensus estimate stock have zack rank hold segmental distribution segmentrevenue segment be year year basis operate income be year year pharmaceutical distribution witness favorable result quarter courtesy ofsolid expansion revenue gross profit include acquisition however lower sale pharmedium operate loss profarma unit partially offset growth corporation price consensus ep surprise corporation price consensus ep surprise corporation quote other segment include consult service abcs world courier mwi veterinary supply revenue segment come year year growth segment be drive consolidation specialty joint venture brazil revenue mwi abcs growth canadian operation world courier business however operate income segment be quarter year year downside be primarily cause lackluster performance abcs lash group margin analysisin quarter review register gross profit year year basis percentage revenue gross margin be basis point bps prior year quarter increase gross profit pharmaceutical distribution service boost company margin second quarter operate expense be year year upside be cause buyout duplicate cost implementation new information technology system register operate income year year percentage revenue operate margin contract bps guidance fiscal expect revenue growth range year year basis notably zack consensus estimate revenue be currently peg year year company expect adjust earning share range notably zack consensus estimate earning be currently peg share fall guidance expect adjust operate expense increase range previous range adjust operate income growth be expect be flat year year end second quarter fiscal solid note strong growth pharmaceutical distribution segment strong guidance instill investor optimism stock further joint venture brazil strength mwi unit abcs growth canadian operation prospect world courier business be key positive moment further recent takeover largest independent wholesaler unite state be also positive flip side sluggishness abcs lash group be concern face headwind thank slowdown hepatitis revenue conversion brand drug lower price generic further temporary slowdown pharmedium growth be expect mar company bottom line regard company face lower expect production pharmedium facility earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
69,VAR,ecolab inc ecl free report report first quarter adjust earning cent share beat zack consensus estimate earning also rise year year basis ecolab carry zack rank hold adjust quarterly net sale be year quarter also net sale beat zack consensus estimate segmental analysisglobal industrial sale segment grow year year almost upside be drive major gain water food beverage life science unit europe north america latin america lead global industrial regional growth however acquisition adjust fix currency operate income segment decrease year year basis due higher deliver product cost massive investment business ecolab inc price consensus ecolab inc price consensus ecolab inc quoteglobal increase lead strong growth specialty business line segment witness solid growth north america asia pacific acquisition adjust fix currency operate income rise year year global energy sale rise owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income remain flat year year other sale decline year year however sale segment witness robust growth north america notably other segment now have ecolab colloidal technology unit unit be previously part global industrial reportable segment acquisition adjust fix currency sale rise year year pest elimination unit segment register solid growth north america europe margin company margin quarter review remain pressure owing higher deliver product cost percentage revenue ecolab register adjust gross margin first quarter basis point bps year year basis adjust operate margin first quarter contract bps net revenue however ecolab remain hopeful latest pricing initiative have undertake management be expect boost margin come quarters view upecolab expect full year adjust earning range share previously issue range notably represent increase band year year notably zack consensus estimate be currently peg share percentage revenue adjust gross margin be expect be net revenue be significantly previously issue range second quarter ecolab expect adjust earning range share current outlook reflect increase year year adjust gross margin second quarter be expect be net revenue end first quarter favorable note beating zack consensus estimate count strength pest elimination business other segment decline year year report basis ecolab operate highly competitive market mar prospect long haul believe volatility foreign currency exchange rate remain significant headwind company ecolab face pricing pressure energy segment be likely hurt profit brighter side strong guidance instill optimism stock further europe north america latin america lead global industrial regional growth quarter strength global institutional segment lead growth specialty healthcare business line be also positive robust product portfolio expand customer base be likely drive organic sale long haul earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
70,VAR,maintain streak positive earning surprise perkinelmer inc pki free report report first quarter adjust earning cent share beating zack consensus estimate base waltham lead medtech company report adjust revenue approximately beat zack consensus estimate revenue also surpass year quarter figure stock carry zack rank buy perkinelmer have outperformed industry year time stock have return higher industry return almost segment analytical solution da robust growth end market revenue da totale first quarter year year organic revenue increase year year perkinelmer have be focuse finalize organizational change associate life science business da unit come profit da segment company report first quarter adjust operate income year quarter perkinelmer register high single digit organic revenue growth asia mid single digit organic revenue growth americas europe bric region perkinelmer report solid organic revenue growth drive continue strength brazil india end first quarter management perkinelmer confirm company be now offer product line china da segment perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote further company be also expect close acquisition china expand elemental analysis product da business solid growth life science apply market boost company business china diagnostic segmentrevenue be compare year reflect year year increase reflect improvement organically diagnostic business perkinelmer infectious disease business exclusively serve emerge market continue show strong growth increase mid digit year year basis reproductive health business diagnostic also grow mid single digit year year however apply genomic business be year year basis due lesser expect micro fluidic sale adjust operate income segment come compare first quarter margin analysisadjust gross profit quarter come year year adjust gross margin percentage revenue be quarter basis point bps year year company expect significant gross margin expansion next year adjust operate income perkinelmer come year year adjust operate margin percentage revenue be quarter basis point bps year year guidance full year perkinelmer expect adjust earning share be significantly higher previously issue guidance notably zack consensus estimate be currently peg share significantly company estimate company expect revenue previously issue range zack consensus estimate be currently peg lower company estimate unfavorable foreign exchange environment put solid pressure quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion exit first quarter solid note strong performance da segment growth da be bolster strength lifescience end market informatic profile onesource offer company experience healthy growth major geography asia americas europe bric nation solid prospect elemental analysis product line hold promise furthermore positive guidance solid long term outlook boost investor confidence stock flipside have diversify portfolio unfavorable foreign exchange be primary concern softness industrial end market due unfavorable timing instrument order have be major dampener perkinelmer further company continue acquire large number company increase integration risk also high debt level hinder company expansion plan earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
71,VAR,haemonetic corporation hae free report have be healthy growth trajectory late share company have soar last month ahead index gain stock have market cap past year zack rank strong buy stock have demonstrated continuous uptrend have return remarkable compare index growth value be also higher broader industry rally further stock deliver average positive earning surprise trail quarters positive growth rate also instill investor optimism stock moreover estimate revision trend earning look impressive stock have see zack consensus estimate move time north last day downward revision witness factor drive haemoneticslet take look possible growth propeller surge segmental revenue last quarter plasma revenue massachusett base blood management company be year year basis upside be drive strong performance disposable software particularly unite state additionally hospital business revenue grow back consistent result north america well improve international result key market expand margin last quarter gross margin expand basis point bps year year basis meanwhile operate margin improve bps year year nexsys pcs market seem be upbeat haemonetic recently introduce platform nexsys plasma collection system pcs device be design increase overall plasma yield donor plan embed software upgrade notably device have also receive fda clearance late ce mark expect come spring moreover management expect submission embed software firmware nexsys pcs function ep guidance raise haemonetic up guidance earning range share compare previous projection lift view be indicative continuation overall bullish sentiment surround stock other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
72,VAR,mar issue update research report walgreen boot alliance inc wba free report be currently look forward company modify rite aid contract be expect benefit company long run stock carry zack rank buy lead pharmacy lead health wellbeing company have outperformed broader industry last day stock have decline compare broader industry decrease ahead walgreen boot second quarter fiscal result schedule release mar be upbeat company strength retail pharmacy usa division continue prescription growth account medicare part growth volume expansion previously announce strategic pharmacy collaboration be also particularly encourage revise rite aid store deal have receive regulatory approval last september walgreen boot modify buyout contract help boost top line gain operational benefit also aid company expand optimize retail pharmacy network key market include northeast notably chain store distribution center be company purchase list store be locate primarily northeast southern unite state distribution center be founder dayville ct philadelphia pa spartanburg sc post transaction initial close synergy be expect be realize year moreover increase retail pharmacy international sale buoy optimism additionally be hopeful company decision acquire stake sinopharm hold guoda drugstore china fact provide strong impetus walgreen boot worldwide retail pharmacy business also company acceptance proposal sell portion investment chinese wholesale partner guangzhou pharmaceutical corporation huge amount cash be major positive however walgreen boot face headwind form fierce competition tough industry condition even company continue gain traction growth initiative major mass merchant be flourishing pharmacy business enjoy fair market share notably slowdown generic introduction last few year have be affect walgreen boot margin escalate reimbursement pressure generic drug cost inflation too have be hamper walgreen boot margin significantly other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
73,VAR,edward lifescience corporation ew free report have be healthy growth trajectory late positive tiding regulatory front have be lend company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment edward lifescience have outperformed broader industry last month stock have gain ahead decline industry stock have market cap company year historical growth rate be also favorable compare increase industry gain company have positive earning surprise last quarters also have long term expect earning growth rate headquarter irvine company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise share same time frame let find recent positive trend be sustainable favorable regulatory tidingsin bid strengthen position predictive analytic edward lifescience recently announce approval request fda acumen hypotension prediction index software notably company plan target launch product unite state market be also upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf segment management continue anticipate ce mark enrollment cardiaq valve regard company have already begin treat patient ce mark trial call clasp pascal transcatheter mitral repair program solid guidanceedward lifescience have raise sale expectation high end previously project range adjust ep expectation have also be lift earlier product pipeline developmentwe be encourage edward lifescience focus build pipeline further strengthen foothold operate business company also witness growth emerge portfolio mitral tricuspid repair therapy edward lifescience new ultra system include balloon delivery system next generation sheath technology be expect be available unite state europe late other key picksa few other top rank stock broader medicalsector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
74,VAR,neogen corporation neog free report report adjust earning cent share third quarter fiscal figure beat zack consensus estimate increase year quarter revenue increase year year basis lag zack consensus estimate revenue detailsfood safety segment revenue segment totale solid overall organic growth neogen corporation price consensus ep surprise neogen corporation price consensus ep surprise neogen corporation quote company witness rise sale neogen rapid diagnostic detect food allergen include gluten milk soy peanut quarter company witness rise sale general sanitation product year quarter sale foodborne pathogen detection test increase include rise sale test detect also sale test kit detect drug residue milk rise quarter animal safety segment segment record revenue reflect increase year quarter growth segment be mainly drive increase sale genomic business rise rodent control product line uptick sale animal care product increase sale drug detection product hike sale detectable needle genomic business unit record increase year year basis management growth be drive september acquisition neogen australasia genomic laboratory australia upside be also drive increase revenue genomic testing beef dairy cattle swine poultry companion animal other exist location margin detailsadjust gross margin expand basis point bps quarter largely drive cost improvement genomic service business favorable product mix animal safety product line adjust operate income be sale third quarter compare year takeneogen exit third quarter solid note be encourage year year increase earning revenue well believe neogen be steadily progress back prong strategy also be encourage accretive acquisition expand international footprint drive overall result fiscal market be look forward company recent launch betastar advanced test beta lactam tetracycline antibiotic milk zack rank key picksneogen carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
75,VAR,resm inc rmd free report have be gain investor confidence consistently positive result stock have gain year versus decline broader industry fall moreover company have market cap year historical growth rate be also favorable compare industry consider solid prospect zack rank buy stock be attractive bet investor moment factor act favorlet take look possible growth propeller solid performanceresm exit second quarter promising note better expect earning revenue encouragingly note company achieve solid double digit revenue growth quarter lead sale software service business well new mask product device grow international businessin second quarter fiscal revenue unite state canada latin american country grow low double digit year year europe asia other market grow mid double digit growth be particularly strong france japan well australia new mask sale internationally be impressive reflect strong adoption mask product notably resm continue invest expand presence high growth market china south korea india brazil many country eastern europe solid horizon growth strategyresm have identify horizon growth term progress first horizon focus resm core sleep apnea franchise company have be make advanced technology combine digital health connect care solution second horizon be growth adjacent product geographic market include homecare ventilation chronic obstructive pulmonary disease amyotrophic lateral sclerosis other respiratory disorder regard company also recently inform first self brand portable oxygen concentrator mobi subject fiscal third quarter launch fiscal first quarter company re launch portable oxygen concentrator call activox company be also focuse grow emerge market china india brazil third growth horizon incorporate portfolio opportunity new market include clinical adjacency such atrial fibrillation heart failure preserve ejection fraction asthma chronic disease management well sleep health wellness focus product developmentin order maintain leadership position sdb market drive sale resm be focuse product development innovation regard company launch airtouch full face mask unite state fiscal fourth quarter airtouch ultrasoft memory foam cushion be breakthrough treatment sleep apnea accord company be well position fiscal work pipeline new product connect care solution sleep apnea copd neuromuscular disease other clinical adjacency other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
76,VAR,ango free report be set report fourth quarter fiscal result jul market open last report quarter company report adjust earning cent share beat zack consensus estimate improve year year net sale fall almost year year miss zack consensus estimate company deliver average positive earning surprise trail quarters quarter be report zack consensus estimate earning be peg cent reflect rise year year further zack consensus estimate sale isat show increase year yearlet see thing be shape prior announcement angiodynamic inc price consensus angiodynamic inc price consensus angiodynamic inc quotefactor drive expand product pipeline international market expansion cost save initiative provide considerable growth opportunity fourth quarter angiodynamic be lead provider minimally invasive medical device used vascular access surgery peripheral vascular disease oncology company product line include ablation system fluid management system vascular access product angiographic product accessory angioplasty product drainage product thrombolytic product venous product be expect boost company sale quarter be report further company continue witness healthy demand coveted nanoknife system treat tumor increase penetration device contribute revenue company oncology division fact recent regulatory approval volta radiofrequency ablation device japan be also significant positive quarter be report company be already look broaden commercial opportunity germany denmark company be also look forward achieve same europe unite kingdom third quarter growth fluid thrombus management product line be offset decline venous insufficiency angiographic catheter business further decline piccs product line lower sale related discontinue rfa product line dampen sale growth believe headwind persist fourth quarter model predict however quantitative model do not conclusively show earning beat angiodynamic quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp angiodynamic currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank angiodynamic currently carry zack rank increase predictive power esp however esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model show have right combination element post earning beat quarter medical group wmgi free report have earning esp zack rank varian medical system inc var free report have earning esp zack rank dexcom inc dxcm free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
77,VAR,varian medical system inc var free report be set report first quarter fiscal result jan market close previous quarter company report adjust earning share miss zack consensus estimate further adjust earning decline year quarter average company deliver negative earning surprise trail quarters also lackluster price performance be woe last year stock have return compare industry rally let see thing be shape prior announcement varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotefactor playdecline financial varian medical experience decline revenue fourth quarter trend be expect continue quarter be report well lackluster performance company halcyon cancer treatment device hamper sale latin america fact sale halcyon platform decline latin america fourth quarter thank several tender push mainly public sector deal revenue asia pacific japan be also expect decline significantly due plummet order halcyon further softness market freestand clinic be headwind varian medical be report quarter performance proton therapy unit have be dampen due intense competition niche space be anticipate be major concern varian medical narrowing customer base majority varian medical ray tube flat panel detector sale cater small number large imaging system original equipment manufacturer oem customer equipment manufacturing major incorporate ray product own medical diagnostic imaging system industrial imaging system due pattern client concentration loss client have adverse effect varian medical operate result earning whispersbuoy factor proven model do not conclusively indicate earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate be peg cent zack consensus estimate be cent uncover best stock buy sell re report earning esp filter zack rank varian medical currently carry zack rank sell decrease predictive power esp make surprise prediction difficult caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model have right combination element post earning beat quarter abbvie inc abbv free report have earning esp zack rank agio pharmaceutical inc agio free report have earning esp zack rank see complete list today zack rank stock here alexion pharmaceutical alxn free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
78,VAR,here be stock add zack rank strong sell list today varian medical system inc var free report be designer manufacturer medical device software product treat cancer zack consensus estimate current year earning have be revise downward last day urstadt biddle property inc uba free report be owner operator self administer equity real estate investment trust zack consensus estimate current year earning have be revise downward last day skywork solution inc swks free report be designer manufacturer semiconductor product zack consensus estimate current year earning have be revise downward last day shaw communication inc sjr free report be owner operator diversify communication company zack consensus estimate current year earning have be revise downward last day pretium resource inc pvg free report be explorer developer precious metal resource property zack consensus estimate current year earning have be revise downward last day view entire zack rank list
79,VAR,here be stock add zack rank strong sell list today netease inc nte free report be interactive online community person republic china zack consensus estimate current year earning have be revise downward last day martin marietta material inc mlm free report be supplier aggregate product heavy build material zack consensus estimate current year earning have be revise downward last day sanderson farm inc safm free report be integrate poultry process company zack consensus estimate current year earning have be revise downward last day varian medical system inc var free report be designer medical device software product zack consensus estimate current year earning have be revise downward last day daniel company adm free report be company involved process merchandising agricultural commodity product zack consensus estimate current year earning have be revise downward last day view entire zack rank list
80,VAR,accuray incorporate aray free report recently receive atomic energy regulatory board aerb type approval flagship radixact system india notably approval establish safety standard system enable hospital india import next generation tomotherapy platform radixact system be fully integrate accuray precision treatment plan system tps idms datum management system notably apollo hospital chennai new delhi have acquire radixact system company march read more accuray radixact picked india apollo cancer treatment accuray exposure ai medical mechatronicsthe latest regulatory approval signify continue momentum coveted radixact system strengthen accuray foothold use artificial intelligence ai mechatronic be currently shape medtech fraternity cision global medical device market be expect reach estimate cagr mechatronic high end technology incorporating electronic machine learn mechanical engineering have be vogue late grow prominence ai robotic company organization significant exposure mechatronic have be rake huge profit consequently accuray latest achievement be likely prove beneficial company long haul radixact drife accurayaccuray recently announce launch precision treatment plan system system leverage company flagship radixact cyberknife system platform company also plan build technology precision upgrade fiscal fact third quarter fiscal accuray witness gross order substantial contribution radixact system moreover radixact system represent tomotherapy order volume price performancein past month accuray share have rally industry decline zack rank key picksaccuray currently carry zack rank strong sell few better rank stock medtech space solid exposure medical mechatronic be abiom abmd free report varian medical system var free report stryker corporation syk free report abiom flagship product impella be world smallest heart pump offer hemodynamic support heart stock sport zack rank strong buy see complete list today zack rank stock here varian medical coveted halcyon hyperarc platform deserve mention stock carry zack rank buy stryker fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
81,VAR,medical instrument industry broader medical universe have be gain innovation higher consolidation focus emerge market tax abolition industry increase month time higher index rise fundamentally industry have benefit massive change consumer behavior well be evident rise minimally invasive surgery higher demand liquid biopsy test well use quick improve patient care shift payment system value base model be interesting analyze best medical instrument stock be likely yield solid return day come first let glance latest headline space latest medical instrument headline glance stryker takeover plan boston medical instrument fraternity have be ride current merger acquisition trend recent report reuter stryker corporation syk free report be likely take boston scientific corporation bsx free report create market value more however possibility deal be uncertain thre be confirmatory statement press release company representative fact investor never forget stryker highly rumore acquisition plan nephew never materialize brighter side be not first time stryker have be tie boston scientific company acquire boston scientific neurovascular unit indicate probability second collaboration read more stryker likely acquire boston scientific stryker have zack rank buy deal materialize combine entity have medtech broadest spectrum product offering include cardiology orthopaedic surgical supply neuroscience reduce pricing pressure competition further company strong acquisition policy gain rapidly expand customer base moderate leverage enhance cash flow glance major acquisition recent past becton dickinson company takeover bard johnson johnson buyout covidien deserve mention abiom reserve slot lead medical instrument player abiom inc abmd free report replace wyndham worldwide corp enter global industry classification standard gic health care supply sub industry index research report globe mail abiom be follow trend medical device technology company reserve top slot index remind investor align technology inc algn free report top index abiom currently have market capitalization further company financial viability adequate liquidity reasonable price sector representation have lend competitive edge medical instrument industry read more abiom replace wyndham benchmark tax abolition boost da bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief tax take toll entire medical device industry enactment advanced medical technology association lobbying group tax have negative impact medical innovation result loss defer creation job now deferral encourage activity space repeal tax paradigm be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have invoked massive investment sector top medical instrument existence number player medical instrument industry choose right stock potential yield return be daunting task proprietary zack methodology make fairly simple have take help zack stock screener select favorable stock have select stock have favorable growth style score carry zack rank strong buy research show stock style score combine zack rank offer best investment opportunity see complete list today zack rank stock here varian medical system inc var free report outperformed industry month time stock have return have zack rank zack consensus estimate full year earning be currently peg year year june varian medical system demonstrated comprehensive portfolio advanced brachytherapy solution american brachytherapy society annual meeting development be likely boost varian oncology system segment apart various volumetric modulate arc therapy vmat stereotactic radiosurgery stereotactic radiotherapy brachytherapy unit be significant contributor oncology system company have be gain consistently coveted halcyon platform cost effective radiotherapy cancer treatment system notably company also launch halcyon kilovoltage imaging solid revenue oncology grow adoption particle therapy strong overseas presence particularly emerge country be positive varian have also be go global acquisition agreement recent buyout include sirtex australia coop taiwan partnership ministry health brazil solid guidance fiscal instill confidence intuitive surgical inc isrg free report outperformed industry month stock have rise almost sport zack rank zack consensus estimate full year earning be currently peg year year grow adoption company da vinci system increase procedure volume continuous innovation solid recur revenue base be key catalyst intuitive surgical da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand movement be translate smaller precise movement tiny instrument patient body da vinci have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery da vinci system have make available minimally invasive surgery more patient worldwide recently system have cure patient diagnosed inguinal hernia integer holding corporation itgr free report outperformed industry last month stock have return industry decline zack consensus estimate full year earning be currently peg year year company witness impressive start high organic year year growth earning revenue cardio vascular arm deserve special mention here other segment have also be deliver solid performance strategic divestment advanced surgical orthopedic portable medical wing medplast llc be expect prove profitable quarters ahead company have multus year plan long term development impressive guidance decline operate expense clear debt be other major positive hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
82,VAR,varian medical system var free report recently announce australia base peter maccallum cancer centre also know peter mac have select company flagship eclipse treatment plan system replace exist cancer treatment platform site notably varian register order fourth quarter fiscal eclipse treatment plan system be integrate comprehensive platform support radiation treatment such photon fff beam proton electron external beam low dose rate brachytherapy cobalt therapy system create optimized radiotherapy treatment plan patient platform be supposedly first microsoft azure host system be deploy australia fact latest development include introduction varian velocity platform peter mac adaptive radiotherapy newer application gain continue witness strong market acceptance software solution particularly eclipse treatment plan aria oncology information system other new application such rapidplan multus criterium optimization insightive analytic solution oncology cloud base cancer operate platform velocity longitudinal cancer imaging solution have be fortify company foothold launch halcyon hyperarc platform be noteworthy platform be used cancer treatment image guide volumetric intensity modulate radiotherapy varian operate technology drive environment success depend innovation frequent product update company have be successful front evident year year expansion top line company other varied offering include truebeam edge platform qumulate qa rapidplan knowledge base treatment plan believe varian innovative product pipeline continue drive overall growth long term market potentiala research report market market suggest global radiotherapy market be project reach worth cagr further global information inc suggest radiotherapy market apac be expect reach worth cagr period report apac have be segregate geographical division australia be major contributor radiotherapy revenue varian have be key player region follow elekta ab ektay free report accuray inc aray free report international growth focusin november varian announce plan open facility jundiai brazil reflect long term commitment partnership brazilian ministry health facility provide access advanced radiotherapy treatment latin america particularly brazilian oncology market development closely follow receipt shonin approval japan ministry health labor welfare market varian halcyon system price performanceyear date varian have outperformed industry term price performance share have return compare favorably sub industry rally just also current return be higher gain zack rank key pickvarian have zack rank sell better rank stock broader medical space be cooper company inc coo free report stock sport zack rank strong buy have long term expect earning growth rate see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
83,VAR,share merit medical system inc mmsi free report have gain release first quarter result apr rally be backed better expect earning share ep revenue growth product line strong performance geography past month company have gain significantly outperform industry decline let delve deep release company report adjust ep cent beat zack consensus estimate earning rise prior year quarter revenue detailin first quarter worldwide revenue totale report basis beating zack consensus estimate constant currency cc revenue come revenue inched cc meanwhile core revenue gross cc management organic growth be mainly drive catheter endoscopy inflation device sale moreover sale unite state china asia pacific europe middle east africa contribute overall growth merit medical system inc price consensus ep surprise merit medical system inc price consensus ep surprise merit medical system inc quotesegmental utah base manufacturer proprietary disposable device report revenue segment cardiovascular endoscopy revenue cardiovascular segment gross significant year year basis meanwhile endoscopy sale totale year marginsin report quarter gross profit come year year gross margin be basis point bps income operation gross notably operate margin expand bps however operate expense shot year year basis rise be mainly lead surge selling general administrative expense rise guidancemerit medical do not provide guidance however buoy solid first quarter management expect solid margin improvement quarters come takemerit medical exit first quarter solid note strong sale segment geography solid organic growth buoy optimism diversify product portfolio active product be major positive new biopsy device pipeline be also encourage additionally approval company distal access sync be promising management be optimistic acquisition complete fourth quarter asset purchase becton dickinson improvement operate margin be positive flip side company decline gross margin year year rise operate expense be discourage moreover management have not issue guidance quarters ahead zack rank key picksmerit medical currently carry zack rank hold few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus mark abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be surpass consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale surpass zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
84,VAR,quality system inc qsii free report report fourth quarter fiscal adjust earning cent share beating zack consensus estimate however adjust earning decline year year basis meanwhile share quality system have rally industry decline past month quality system also know nextgen healthcare currently carry zack rank hold revenue detailrevenue fiscal fourth quarter totale also beat zack consensus estimate revenue rise year quarter management year year booking totale fourth quarter constant currency cc notably company flagship nextgen mobile platform see best quarter so far term booking secure large client base segment detailsquality system report fiscal fourth quarter revenue follow segment total software hardware related segment register revenue worth year year upside be attribute surge software related subscription service rise management growth be drive nextgen office solution formerly know meditouch contribution analytic mobile solution quality system inc price consensus ep surprise quality system inc price consensus ep surprise quality system inc quotesupport maintenance segment see soft quarter revenue decline year revenue cycle management rcm related service revenue segment come year year basis however management rcm pipeline have solid long term prospect electronic datum interchange datum service revenue segment fall marginal professional service segment gross revenue increase whopping prior year quarter transcription revenue entrada acquisition marginsgross profit report quarter decline year year gross margin contract basis point bps operate loss be quarter operate expense shot drive surge sg selling general administrative expense totale huge year year basis however research development expense contract quarter balance sheet company exit fiscal cash cash equivalent fiscal glanceon full year basis adjust earning share come cent beat zack consensus estimate cent however earning deteriorate year full year revenue totale also beat zack consensus estimate notably revenue rise prior year figure company provide initial view fiscal revenue be project range zack consensus estimate fiscal revenue be peg lie give range adjust earning be expect cent fiscal zack consensus estimate fiscal earning be pin cent again be range takequality system exit fiscal fourth quarter solid note management foresee solid growth prospect rcm pipeline acquisition entrada eagle dream have proven accretive moreover nextgen population health analytic suite nextgen mobile platform register significant growth fourth quarter company witness solid booking growth sequential year year basis solid guidance fiscal also hold promise flip side dull performance rcm electronic datum interchange segment be major headwind moment further contract gross margin surge operate expense raise concern company expense have contract indicate reduce focus innovation quality system also be broadly expose integration risk cutthroat competition niche space add wo key picksa few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be surpass consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale surpass zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus mark look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
85,VAR,month have go last earning report varian medical system inc var free report share have lose time frame recent negative trend continue lead next earning release be var due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent streak positive earning surprise varian medical system report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning also improve year year basis revenue totale beat zack consensus estimate year year basis revenue increase cc company have strengthen foothold radiation therapy market grow order basis trail month let delve deeper company quarterly result segment detailsoncology systemsin say quarter oncology revenue totale cc year year basis varian worldwide net install base be unit unit year year basis whole gross order be year quarter cc gross order americas inched year year basis cc emea gross order be flat year year apac gross order increase year year operate earning segment rise year year february varian acquire small privately hold quality assurance software company mobius medical system management mobius market lead software doselab be solid enhancement varian exist portfolio patient treatment plan qa machine qa technology strong performance software hardware service revenue boost varian oncology system report quarter particle therapyrevenue segment inched year year basis notably company do not book new probeam order quarter march varian announce first patient treatment st petersburg proton therapy center russia important step expand access proton therapy world halcyon drive revenuesin second quarter halcyon platform witness total order inception majority greenfield site reflect solid demand platform quarters ahead anticipate growth be drive solid new scale configuration optimized different customer segment advanced capability marginstotal company gross profit report quarter be year year gross margin report quarter be expand basis point bps year year basis oncology gross margin report quarter be percentage revenue basis point be primarily drive revenue growth hardware software service margin rate expansion europe pricing discipline ongoing operational excellence financial company end quarter cash cash equivalent debt cash flow operation be year year drive operate income performance work capital efficiency fy annual guidance revenue growth be expect range year year basis fiscal adjust operate earning percentage revenue be expect range adjust earning share be expect range cash flow operation be expect range have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotevgm scoresat time var have nice growth score however momentum be do bit better stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable momentum investor also be suitable look growth lesser degree value outlookestimate have be broadly trend upward stock magnitude revision have be net come little surprise var have zack rank buy expect average return stock next few month
86,VAR,veeva system inc veev free report report first quarter fiscal adjust earning cent share bottom line beat zack consensus estimate cent improve year quarter figure total revenue be first quarter year year moreover top line surpass zack consensus estimate veeva system strong growth subscription revenue segment drive metric veeva system outperformed industry year date basis company share have gain compare favorably industry rise current level be also higher index return just stock have zack rank hold segmental detailsfirst quarter subscription service revenue be year year upside be backed stronger expect booking quarter review subscription gross margin be expand roughly basis point bps year year company momentum product line especially veeva vault continue drive growth professional service revenue rise almost quarter review service gross margin be bps prior year quarter veeva system inc price consensus ep surprise veeva system inc price consensus ep surprise veeva system inc quotemargin profit report quarter increase year year gross margin veeva system contract bps report quarter operate income be report quarter year quarter level however operate margin contract bps year quarter figure rise operate expense have keep operate margin pressure quarter regard operate expense increase report quarter research development expense increase sale marketing expense rise general administrative expense increase company provide financial guidance second quarter fiscal total revenue be expect range zack consensus estimate be peg be guidance adjust operate income be expect adjust earning share be expect band cent zack consensus estimate be peg cent be guidance fiscal total revenue be anticipate band previous range zack consensus estimate be peg lie guidance adjust earning be project previous range zack consensus estimate metric be peg lie guidance conclusionveeva system exit first quarter fiscal solid note beating zack consensus estimate count solid performance subscription revenue have be key catalyst further bid replace simple custom make datum warehouse unique industry specific datum model veeva system recently introduce veeva nitro new model commercial datum warehouse life science be encourage veeva system consistent effort product innovation launch grow global demand cloud base vault application also boost opportunity flip side high expense operational side be cause drag company margin partially dampening revenue furthermore intense competition saturating life science market be key concern volatility foreign currency exchange rate be headwind earning medtech major glancea few better rank stock broader medical space report solid earning season be boston scientific corporation bsx free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here varian medical report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis stock have zack rank buy boston scientific post adjust earning share cent first quarter year quarter tally earning also surpass zack consensus estimate cent stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
87,VAR,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report recently announce have initiate treatment recently introduce halcyon system treatment be provide penn medicine patient suffering head neck cancer notably treatment used halcyon platform be cost effective be short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon unit glancevarian medical have be take initiative gain customer broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna third quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide halcyon receive clearance ce mark european directive allow varian medical start selling system unite state management regulatory clearance china japan follow next year quarter varian medical book several order country australia belgium india morocco romania russia turkey market prospectsstrong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian medical datum market market reveal global radiotherapy market be project reach worth cagr meanwhile other important stock broader medical sector be zimmer biomet holding zbh free report abiom inc abmd free report intuitive surgical isrg free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
88,VAR,cooper company inc coo free report be top perform stock medtech space company be likely gain expand product portfolio increase penetration international market stock have rally year time industry decline index fall stock have market cap past day zack consensus estimate earning share inched share full year company have zack rank buy indicate possibility outperformance term cooper company inc price consensus cooper company inc price consensus cooper company inc company deliver average earning surprise trail quarters also expect long term earning growth look promising let find company maintain recent positive trend cooper company coopervision segment be key growth driver segment gain silicone hydrogel lense lead solid prospect myday clariti biofinity platform fact company flagship silicone hydrogel lense be expect deliver strong sale upcoming quarters company have initiate process introduce myday lense domestic market be already available europe have gain significant traction short span clariti lense also hold significant growth prospect company outlook contact lens industry be favorable fall dropout rate contact lens wearer further market penetration especially develop nation be expect growth international market be something contact lens manufacturer be banking accord report grand view research global contact lense market be estimate reach worth thus company expect prospect market cooper company be progress well inorganic expansion well recently company acquire asset lifeglobal group lead global provider fertilization ivf device affiliate management acquisition perfectly fit company fertility solution portfolio key picksa few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
89,VAR,bid enhance food safety deliver world class warewashing result restaurant ecolab inc ecl free report recently launch smartpower program notably platform focus be warewashing process collect dirty kitchen ware cutlery washing rinsing dynamic smartpower platform reduce labor water energy cost management program be rolled year unite state later europe believe latest development be likely help ecolab fortify position food hygiene space fact company recently launch dynamic health department intelligence hdi platform well focus food safety hdi platform retrieve manage health department inspection datum foodservice operator provide insight help address food safety risk help company improve health inspection performance manage food safety risk efficiently read more ecolab roll hdi improve food surveillance support development ecolab share have rally compare industry rise year time smartpower smartpower be complete warewashing program used proprietary chemistry advanced cloud compute provide skilled service result cost effective operation especially restaurateur management advanced new chemistry help decompose buildup ware prevent soil reattach moreover real time insight warewashing performance personalize service help customer identify trend operation reduce customer daily dish rack thereby lower total cost positive result follow extensive testing foodservice environment country management user smartpower have report significant increase ware usable guest first wash eliminate need rewash accord bizfluent labor be single largest expense category majority restaurant average labor cost financially sustainable restaurant be gross sale go pay wage earn staff such server additional go pay salaried worker such manager use real time datum application have help company bolster footprint healthcare space market prospectsper orbis research industry analyst forecast commercial food service equipment market unite state witness cagr period other hand opine global healthcare solution market be expect reach cagr period thus be conclude ecolab move have be timely strategic zack rank key picksecolab currently carry zack rank hold few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
90,VAR,varian medical system inc var free report recently announce st petersburg center nuclear medicine sergey berezin medical institute conclude first pediatric patient treatment company flagship probeam proton therapy system notably center be expect treat approximately patient year solid prospect zack rank buy stock be attractive pick moment be probeam proton therapy system varian medical probeam system be lead platform advanced cancer care technology be world first commercially available pencil beam scanning system be most precise form proton therapy available platform come company particle therapy business deliver intensity modulate proton therapy impt be consider be better other legacy proton therapy delivery method last quarter varian medical book new proton order university alabama birmingham sylvester comprehensive cancer center university miami management confirm order be probeam system varian medical system inc price varian medical system inc price varian medical system inc quotefavorable stock performanceover past year varian medical outperformed industry term price performance company return compare favorably sub industry gain also current return be higher growth varian medical solid performance oncology business probeam proton therapy improve margin launch halcyon radiotherapy treatment system be key highlight moment strong revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be also positive other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
91,VAR,phibro animal health corporation pahc free report have be gain investor confidence consistently impressive result stock have surge past year ahead rally broader industry rise moreover company have market cap earning growth rate be also favorable compare industry increase arm solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have also be positive last day analyst revise estimate upward movement noticed opposite direction stock have see zack consensus estimate earning be revise upward share style score phibro sport growth score reflective company strong bright future research show stock growth style score combine bullish zack rank strong buy offer best upside potential regard lead global diversify animal health mineral nutrition company have favorable net margin net income sale industry negative company sale asset ratio compare industry underline stock attractiveness lucrative option let find recent positive trend be sustainable solid second quarter fiscal end second quarter fiscal encourage note company witness considerable improvement segment moreover believe continuous investment portfolio enhancement develop organizational capability have start pay solid guidancewe be also upbeat raise guidance fiscal indicative stock bull run continue rest impressive effort grow emerge marketsphibro exist operation establish sale marketing well distribution network more country provide company ample scope take advantage global growth opportunity outside unite state phibro international footprint extend key high growth region country expect higher livestock production growth rate average tally include brazil other country south america china india asia pacific russia former cis commonwealth independent state country mexico turkey australia canada south africa apart other country africa phibro have continue invest far east belt have huge growth potential poultry dairy industry strong animal health businessanimal health segment have remain key contribute business deliver positive growth year year management believe company be well position fastest grow food animal species segment animal health market significant presence poultry swine project vetnosis grow worldwide compound annual rate respectively such optimistic trend prevalent market phibro animal health business be bound perform well other key picksother top rank stock broader medical sector include bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
92,VAR,intuitive surgical inc isrg free report be top perform stock medtech space grow adoption company robot base da vinci surgical system increase procedure volume be key catalyst stock have rally year time industry decline index return stock have market cap let find company maintain positive trend robot base da vinci unit drive grow prevalence minimally invasive robot assist surgery self automate home base care use quick improve patient care shift payment system value base model indicate higher adoption artificial intelligence medtech space intuitive surgical flagship da vinci surgical system be power robotic technology platform have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery da vinci system have provide minimally invasive surgery more patient worldwide company launch upgrade flagship vinci xi technology notably xi suite be design seamlessly integrate future innovation such advanced instrumentation surgical skill simulation software upgrade other advancement dynamic platform company now ship xi single site xi millimeter stapler firefly several country minimally invasive surgery be become increasingly popular help patient recover faster thereby reduce hospitalization cost notably minimally invasive surgical instrument market be project reach worth cagr market market high price da vinci system hinder widespread adoption believe overwhelming benefit minimally invasive surgery compel surgeon patient use system drive company system sale improve top line growth long run first quarter da vinci procedure grow approximately year year intuitive surgical replace da vinci surgical system first quarter company install base grow year quarter company have strong opportunity general surgery market particularly drive procedure hernia repair colorectal surgery internationally company have significant opportunity japan south korea china zack rank estimate revisionin past day zack consensus estimate earning share increase current quarter intuitive surgical sport zack rank strong buy indicate possibility outperformance term see complete list today zack rank stock here company deliver average earning surprise trail quarters also expect long term earning growth look promising intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quote other key picksa few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
93,VAR,mckesson mck free report report fourth quarter fiscal earning share miss zack consensus estimate earning however improve year quarter figure mckesson post sale marginally miss zack consensus estimate constant currency cc quarter detailmckesson operate segment distribution solution technology solution however report quarter company do not report detail technology solution unit distribution segment report revenue quarter cc fact segment account whole company fourth quarter revenue mckesson corporation price consensus ep surprise mckesson corporation price consensus ep surprise mckesson corporation quotenorth america pharmaceutical distribution service revenue come prior year quarter full year revenue segment totale cc rise be attribute market growth acquisition have be partially offset brand generic conversion international pharmaceutical distribution service report revenue increase year quarter full year revenue segment be cc medical surgical distribution service rake revenue improve year year basis full year segment post revenue worth year marginsgross profit report quarter be year year basis gross margin be basis point bps operate expense rise year year basis fy glancefull year adjust earning share grow year include cent diluted share contribution create profit foundation report figure miss zack consensus estimate be peg revenue fiscal gross compare year figure marginally miss zack consensus estimate be pin fiscal cash flow operation totale mckesson end year cash cash equivalent fiscal mckesson repay approximately net long term debt share repurchase company board director authorize additional share repurchase program expect adjust earning share fiscal notably zack consensus estimate fiscal earning be peg give range free cash flow be expect fiscal guidance assume full year adjust tax rate approximately vary quarter quarter management fiscal outlook represent mid high single digit percentage growth year year reflect more stable market condition takemckesson wrapped fourth quarter fiscal mixed note adjust earning revenue miss estimate moreover solid growth distribution solution segment hold promise surge international sale be major positive however contract gross margin raise concern escalate operate expense be also headwind price fluctuation generic pharmaceutical stiff competition niche space add wo zack rank key picksmckesson currently carry zack rank hold few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be beating zack consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale surpass zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
94,VAR,varian medical system var free report recently install varian probeam cyclotron university college hospital london nhs foundation trust uclh proton beam therapy center notably cyclotron be particle accelerator accelerate proton third speed light clinical use uclh feature treatment room commence treat patient earlier varian medical deliver cyclotron first national health service high energy proton therapy center latest move california base provider cancer care further consolidate global foothold provide proton therapy solution believe such positive development further boost varian share have gain industry decline past month market prospectsper grand view research global proton therapy system market be expect reach increase number proton therapy center rise prevalence cancer hospital focus investment be believe be primary growth driver varian proton therapy magnatevarian medical probeam system be forefront industry have create world first commercially available pencil beam scanning system notably be first kind deliver intensity modulate proton therapy management fiscal varian medical sale pipeline have remain solid proton order company have also be focuse education training continue growth proton therapy world recently varian medical university school medicine reach first educational milestone proton treatment center more medical professional have be trained joint venture furthermore recently st petersburg center nuclear medicine sergey berezin medical institute successfully complete first pediatric patient treatment varian probeam proton therapy system read more varian medical probeam platform gain traction russia earlier varian medical probeam be also select penn medicine academic medical center university pennsylvania additionally company coveted aria information management system eclipse treatment plan system be also picked penn medicine zack rank other stock considervarian medical currently flaunt zack rank strong buy few other top rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
95,VAR,share medidata solution inc mdso free report have gain release first quarter result apr rally be backed better expect earning share ep revenue growth segment past month company have gain significantly outperform industry return zack rank hold company report adjust ep cent outpaced zack consensus estimate earning improve prior year quarter quarter first quarter gross year revenue beat zack consensus estimate management be optimistic broaden customer base owing significant enterprise agreement sign first quarter medidata solution inc price consensus ep surprise medidata solution inc price consensus ep surprise medidata solution inc quotesegment revenue come year year basis management total subscription backlog increase year year basis more revenue professional service gross prior year quarter marginsin first quarter gross profit come year year gross margin be impressive contract basis point bps adjust operate income totale year year basis adjust operate margin be bps company have retain guidance total revenue be expect represent year year growth notably zack consensus estimate be peg project range subscription revenue be anticipate professional service be expect garner approximately gaap operate income be expect gaap net income be project wrapped first quarter solid note strong growth record subscription segment be major positive improvement operate margin buoy optimism company also ride newly sign enterprise agreement quarter be likely broaden customer base furthermore medidata be gain momentum area payment etmf imaging mhealth company coveted rave genomic platform be also see slew development management foresee tremendous scope research development well flip side decline gross margin raise concern company also face stiff competition niche space key picksa few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be surpass consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale beat consensus mark intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus mark more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
96,VAR,unite state be largest medical world rake dollar revenue annually abiom inc abmd free report varian medical system inc var free report be solid contender space abiom flaunt zack rank strong buy varian medical carry zack rank buy stock have growth score research show stock growth score combine zack rank be better pick most here take detailed look fundamental company determine stock be currently position better medical instrument space market cap abiom be engage develop manufacturing marketing medical product design assist replace pump function heart failure varian medical be lead provider radiotherapy radiosurgery proton therapy brachytherapy world california base company currently have market cap price performancein past month share abiom have rally whopping significantly outperform industry decline comparison share varian medical have also outperformed industry gain same time frame notably bothmstock have also surpass index return same time frame consequently abiom win varian medical price performance be be consider meanwhile see complete list today zack rank stock here earning growth abiom zack consensus estimate current year earning be peg reflect year year growth stock have long term expect earning growth rate other hand same varian medical be peggedat indicate year year growth stock have long term expect earning growth rate abiom win round sale growth zack consensus estimate abiom current year revenue be show year year growth same varian medical be peg reflect year year growth here too abiom win varian medical drive stock abiomedabiom have consistently gain rise coronary heart disease unite state company diverse product line offer minimally invasive procedure help patient overcome stress open surgery moreover company impella product line have be solid growth driver last report quarter witness increase adoption impella product domestically internationally positive likely buoy company join coveted benchmark very recently notably abiom replace wyndham worldwide corp read more abiomedto replace wyndham benchmark varian medicalbeside be strong player oncology treatment market varian medical also have robust international presence particularly emerge economy notably varian medical recently complete major overseas buyout cooperative cl enterprise coop lead distributor radiotherapy equipment taiwan sirtex australia base company focuse interventional oncology therapy bid strengthen oncology system segment varian medical recently announce plan demonstrate company comprehensive portfolio advanced brachytherapy solution read more varian demonstrate brachytherapy solution portfolio conclusionour comparative analysis indicate abiom be well position compare varian medical consider price performance earning growth projection sale expectation other key pickssome other top rank stock broader medical space be genomic health ghdx free report intuitive surgical inc isrg free report genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free unite state be largest medical world rake dollar revenue annually abiom inc abmd free report varian medical system inc var free report be solid contender space abiom flaunt zack rank strong buy varian medical carry zack rank buy stock have growth score research show stock growth score combine zack rank be better pick most here take detailed look fundamental company determine stock be currently position better medical instrument space market cap abiom be engage develop manufacturing marketing medical product design assist replace pump function heart failure varian medical be lead provider radiotherapy radiosurgery proton therapy brachytherapy world california base company currently have market cap price performance past month share abiom have rally whopping significantly outperform industry decline comparison share varian medical have also outperformed industry gain same time frame notably bothmstock have also surpass index return same time frame consequently abiom win varian medical price performance be be consider meanwhile see complete list today zack rank stock here earning growth projection abiom zack consensus estimate current year earning be peg reflect year year growth stock have long term expect earning growth rate other hand same varian medical be peggedat indicate year year growth stock have long term expect earning growth rate abiom win round sale growth projection zack consensus estimate abiom current year revenue be show year year growth same varian medical be peg reflect year year growth here too abiom win varian medical drive stock abiom abiom have consistently gain rise coronary heart disease unite state company diverse product line offer minimally invasive procedure help patient overcome stress open surgery moreover company impella product line have be solid growth driver last report quarter witness increase adoption impella product domestically internationally positive likely buoy company join coveted benchmark very recently notably abiom replace wyndham worldwide corp read more abiom replace wyndham benchmark abiom inc price consensus abiom inc price consensus abiom inc quotevarian medical be strong player oncology treatment market varian medical also have robust international presence particularly emerge economy notably varian medical recently complete major overseas buyout cooperative cl enterprise coop lead distributor radiotherapy equipment taiwan sirtex australia base company focuse interventional oncology therapy bid strengthen oncology system segment varian medical recently announce plan demonstrate company comprehensive portfolio advanced brachytherapy solution read more varian demonstrate brachytherapy solution portfolio varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotein conclusion comparative analysis indicate abiom be well position compare varian medical consider price performance earning growth projection sale expectation other key pick other top rank stock broader medical space be genomic health ghdx free report intuitive surgical inc isrg free report genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
97,VAR,abiom abmd free report first quarter fiscal earning be schedule release jul market open believe company be set gain flagship impella product line impressive guidance fiscal recent upgrade coveted benchmark be other tailwind last report quarter abiom post adjust earning share cent beat zack consensus estimate earning also sky-rocket year quarter figure quarter be report zack consensus estimate revenue be peg reflect year year rise zack consensus estimate adjust earning share be peg cent indicate significant climb abiom inc price ep surprise abiom inc price ep surprise abiom inc quotesolid impella product line likely drive impella be world smallest heart pump abiom flagship product line have continue be growth driver company recently impella heart pump receive ce mark approval europe notably first patient be successfully treat university heart center hamburg germany latest acceptance further enhance abiom product portfolio read more abiom impella receive ce mark europe management await approval impella unite state be expect help abiom significantly advance field heart recovery moreover company impella cp heart pump smartassist also receive fda pre market approval pma additionally abiom have already receive ce mark approval european union market impella cp smartassist last report quarter company witness strong adoption impella product line unite state germany japan management anticipate patient adopt product line germany japan respectively other factor playview fiscal company expect total revenue reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range massachusett base developer medical product replace wyndham worldwide corp join distinguish index portfolio lead company have approximately coverage available market capitalization index be important metric equity hence abiom recent development be proof company solid prospect read more abiom replace wyndham benchmark cutthroat treatment provider heart related disease be intense abiom product compete temporary cardiac assist device throat company also face stiff competition organization develop permanent heart assist product thoratec teleflex heartware jarvik heart microme technology model predictsour quantitative model do not predict earning beat abiom quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate have be illustrated earning esp abiom have earning esp uncover best stock buy sell re report earning esp filter zack rank abiom currently carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp currently stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock presently carry zack rank becton dickinson company bdx free report have earning esp stock currently carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
98,VAR,bid strengthen position predictive analytic edward lifescience corporation ew free report have recently announce approval request fda acumen hypotension prediction index hpi software notably company plan target launch product unite state ce marked adjunctive predictive cardiovascular indicator designate fda come minimally invasive flotrac iq sensor advantage acumen hpi software be assist improve decision make high risk surgical patient used software algorithms predict future cardiovascular event evaluation cardiovascular vital sign furthermore acumen hpi feature go well edward minimally invasive hemodynamic monitoring solution glimpse critical care critical care portfolio include pulmonary artery catheter disposable pressure transducer advanced monitoring system aside have line balloon catheter base product surgical clip insert critical care product group sale totale fourth quarter rise underlie basis solid improvement product category be drive strong growth company core product mainly unite state china also company aim tighten hold critical care technology ongoing rollout hemosphere monitoring platform further expansion enhance surgical recovery program market potentialper report market research global predictive analytic market be expect witness cagr approximately thus latest development have come opportune time company cash bountiful opportunity high potential niche market price performanceover past month edward share have outperformed industry belong stock have rally compare industry rise zack rank other key picksedward carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
99,VAR,baxter international inc bax free report have be healthy growth trajectory late positive tiding regulatory front strategic acquisition have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment baxter international have outperformed industry past year stock have gain outperform gain broader industry stock have market cap company next year earning growth rate be also favorable compare increase company have positive earning surprise last quarters also have long term expect earning growth rate baxter international have impressive growth style score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity let find recent positive trend be sustainable strategic market be upbeat company recent acquisition hemostat sealant product thrombin topical recombinant preveleak surgical sealant mallinckrodt plc solid baxter estimate sale growth approximately constant currency adjust earning full year be expect band share solid estimate revision company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise same time frame positive regulatory market be also encourage note baxter international receive fda approval bivalirudin percent sodium chloride injection bivalirudin other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
100,VAR,ministry health labour welfare mhlw japan grant national reimbursement abbott free report mitraclip therapy move be likely improve company structural heart business mitraclip be fda approve ce marked system also nearly country more person have be treat mitraclip mhlw approve mitraclip system japan november be mitraclip mitraclip therapy be used treat patient mitral regurgitation reimbursement be effective april japan reimbursement entitle patient access therapy country health insurance plan company mitral regurgitation be serious progressive heart disease mitral valve do not close properly allow blood flow backward heart mitraclip system be approve japan treatment severe degenerative mitral regurgitation dmr functional mitral regurgitation fmr heart disease glimpse structural heart businessabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business sale improvement segment be drive double digit growth heart failure structural heart neuromodulation diabetes care last quarter notably structural heart business account total revenue medical device segment upside be lead continue double digit growth mitraclip believe latest development boost company top line recently company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart business market prospectsper report ally market research tanscatheter mitral valve repair replacement market be estimate worth repair replacement valf cagr noteworthy company space be edward lifescience corporation ew free report share price estimate revision trendabbott have be gain investor confidence consistent positive result last month stock have outperformed industry stock have moved comparison broader industry gain current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank key picksabbott carry zack rank hold couple better rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
101,VAR,varian medical system var free report recently announce release fda approve treatment plan software eclipse help clinician treat more accuracy efficiency eclipse also provide treatment plan support varian hyperarc oncology system hdrt efficient automate delivery complex stereotactic radiosurgery hyperarc hdrt be new type radiosurgery treatment eclipse offer graphic process unit gpu support help physician optimize speedily calculate dose eclipse feature multus criterium optimization mco allow clinician explore application different clinical criterium accord company accord company mco focus find optimal plan faster give patient minimal trial error iteration last report third quarter varian medical revenue decline oncology system company be consistently try turn oncology system business apart latest development company recently announce fda clearance revolutionary halcyon product company receive order country system north america company sign agreement petcure oncology bring unprecedented level care pet suffering cancer accord report market market global oncology information system market be expect reach worth cagr consider huge potential market believe latest development be strategic fit past month varian medical have outperformed broader industry term price company have return compare favorably sub industry gain estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share same period zack rank key picksvarian medicalcarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last year idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
102,VAR,varian medical system inc var free report have be healthy growth trajectory late positive tiding regulatory front have lend company competitive edge medtech space solid prospect zack rank buy stock be attractive pick moment varian medical have outperformed industry last month stock have gain higher industry stock have market cap company have positive earning surprise last quarters also have long term expect earning growth rate company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity company estimate revision trend current year have be encourage well past couple month estimate moved north movement opposite direction earning share estimate rise let find recent positive trend be sustainable factor drive varian medicalpositive regulatory tiding varian medical recently announce receipt regulatory clearance antitrust authority german federal cartel office fco acquisition sirtex medical limit transaction be expect strengthen varian medical footprint australia close varian medical equip mexico center instituto mexicano del seguro social imss have select varian medical equip treatment center mexico modern radiotherapy treatment system include edge system image guide stereotactic radiosurgery evinance innovation acquisition varian medical recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company deal be initiate last september varian medical have state utilize evinance patented technology offer better service client other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
103,VAR,bid strengthen oncology system segment varian medical system var free report recently announce plan demonstrate comprehensive portfolio advanced brachytherapy solution company exhibit product line american brachytherapy society annual meeting jun san francisco notably company demonstrate brachytherapy solution conference include brachyvision brachytherapy treatment plan system variseed ldr prostate treatment plan system vitesse real time plan hdr brachytherapy varian brachytherapy applicator accessory varian brachytherapy profile boost oncology announcement be likely boost varian oncology system segment apart various volumetric modulate arc therapy vmat stereotactic radiosurgery stereotactic radiotherapy brachytherapy unit be significant contributor oncology system salesin theoncology system business represent total revenue fiscal respectively first quarter fiscal oncology revenue totale cc year year basis brachytherapy company brachytherapy solution design manufacture sell serve advanced brachytherapy product varisource hdr afterloader gammame hdr pdr afterloader brachyvision brachytherapy treatment plan system other applicator well accessory company brachytherapy also develop market variseed ldr prostate treatment plan system vitesse software real time treatment plan hdr prostate brachytherapy aggressive rivalryhowever cutthroat competition niche brachytherapy space have be headwind varian company compete head head elekta ab mim software inc eckert ziegler bebig gmbh term brachytherapy solution varian manufacture high dose rate brachytherapy system crawley company brachytherapy treatment plan product be manufacture charlottesville virginia varian medical system inc price consensus varian medical system inc price consensus varian medical system inc market be alternative external beam radiotherapy process involve insertion radioactive seed wire ribbon directly tumor body cavity tumor brachytherapy be often used cancer head neck breast uterus cervix soft tissue well prostate recent research report grand view research global brachytherapy market be expect reach courtesy increase geriatric population lifestyle issue underpenetrated emerge economy consider solid prospect global market latest development be expect bolster varian foothold brachytherapy market medtech space favorable stock outperformed industry year time company share have return industry fall also current return be higher index rise zack rank other key picksvarian sport zack rank strong buy few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank see complete list today zack rank stock here genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
104,VAR,allscript healthcare solution mdrx free report recently close previously announce acquisition florida base healthgrid hold company deal value cash buyout be likely significantly expand company followmyhealth platform patient engagement solution connect consumer provider latest development be likely drive allscript share have rally compare industry gain year time followmyhealth be ehr electronic health record base patient engagement platform combine personal health record patient portal health information exchange hie management majority allscript client use followmyhealth close deal allscript aim integrate healthgrid capability flagship followmyhealth platform help provider reach patient population require patient sign portal notably healthgrid be lead mobile enterprise patient engagement solution help hospital health system improve patient outcome latest development help allscript offer most comprehensive patient engagement solution allscript ehrin recent past allscript have diversify ehr base acquire mckesson corporation hospital health system business also know enterprise information solution eis have lend eis customer access allscript coveted population health management solution careinmotion revenue cycle management service improve patient outcome accelerate transition value base care other flagship ehr platform include allscript professional ehr open platform solution bring information source harmony create open connect community health moreover allscript touchwork ehr be build offer clinical decision support point care prescribe configurable clinical desktop nearly clinician review care guide company have also launch avenel next generation cloud base ehr build microsoft azure create community wide share patient record market prospectsper research global prescribe market be project reach cagr increase government initiative incentive program rise focus reduction fraud abuse controlled substance focus reduce medical error be drive market zack rank key picksallscript carry zack rank hold better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
105,VAR,initiative boost customer base algerium lead medical device software manufacturer varian medical system inc var free report recently announce conduction day workshop radiotherapy practitioner country varian have system operate algerium moment latest development signify company long term goal serve cancer patient year workshop demonstrate advanced prostate head neck treatment technique be attend clinical team regional hospital latest development be collaboration algerian ministry health help clinician use varian technology deliver advanced radiotherapy cancer patient algerium fact first varian linear accelerator be install year country varian also inked deal algerian ministry equip country cancer treatment center company technology radiotherapy radio surgery meanwhile varian solid performance radiotherapy business improve margin launch halcyon radiotherapy treatment system be key highlight furthermore strong revenue opportunity several oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership be key positive varian have be consistently expand internationally long fact company have receive order australia belgium india morocco romania russia turkey unite kingdom last quarter regard varian proton therapy unit have seal deal bangkok base king chulalongkorn memorial hospital earlier year march brazil base moinhos hospital initiate cancer treatment country used varian technology precisely moinhos used company flagship product calypso tumor tracking system cancer treatment varian have zack rank hold past month varian medical have outperformed broader industry term price company have return compare sub industry also current return be higher gain same time frame key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
106,VAR,aug issue update research report palo alto base varian medical system inc var free report company be world lead provider radiotherapy radiosurgery proton therapy brachytherapy treat cancer other medical condition varian medical have unimpressive run bourse last month trading industry term price performance glimpse share price movement reveal varian medical share have lose compare unfavorably decline industry look forward varian medical oncology proton therapy business growth prospect remain impressive company be address tier mid tier market edge truebeam vitalbeam halcyon product company be winning contract not only americas also emerge international market be huge positive believe china africa present significant top line growth opportunity term company be open new office africa middle east provide growth opportunity region varian medical operate technology drive environment success depend innovation frequent product update company have be successful front evident year year growth top line company have approximately revenue opportunity various oncology imaging component product next year varied offering include truebeam edge platform insightive analytic qumulate qa rapidplan knowledge base treatment plan believe varian medical innovative product pipeline continue drive growth long term apart enjoy dominant market share conventional radiotherapy believe proton therapy also hold significant promise varian medical be probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor cause lesser side effect surround tissue proton therapy system used same interface used company truebeam platform finally company strong overseas presence be expect enable leverage opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly asia be grow faster rate domestic market flip side unfavorable currency translation continue be major dampener stock management fear further strengthen dollar foreign currency lead deteriorate operate result intense competition well possibility varian medical new test not generate meaningful profit outweigh cost associate development continue raise concern zack rank key picksvarian medical carry zack rank hold better rank medical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month steris have positive earning surprise trail quarters stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
107,VAR,palo alto base manufacturer medical device software varian medical system inc var free report announce have sign distribution agreement toledo base bionix radiation therapy agreement varian medical distribute bionix propreitory brachytherapy applicator varian market bionix esophageal applicator app anorectal applicator ar north america applicator app be disposable brachytherapy applicator be design specifically treatment cancer app feature independently operable balloon maintain central position source catheter straight curved anatomy allow closer proximity target source maintain distance healthy tissue second applicator ar be disposable brachytherapy applicator be design specifically treatment anal rectal cancer dual balloon design ar allow exophytic tumor press closer source catheter create ability deliver very high dose tumor spare healthy tissue future trendwe note global radiotherapy market be expect reach worth cagr take bountiful prospect global niche space consideration latest development boost investor confidence share price performancea promising portfolio combine robust initiative have be favore zack rank hold company have deliver positive earning surprise last quarters note share varian medical have decline past month broader industry grow same time frame takevarian medical operate technology drive environment success depend innovation frequent product update company have be successful front evident year year expansion top line company have approximately revenue opportunity various oncology imaging component product next year apart enjoy dominant market share conventional radiotherapy believe proton therapy hold significant promise varian medical be probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor cause lesser side effect surround tissue proton therapy system used same interface used company truebeam platform finally company strong overseas presence be expect enable leverage opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly asia be grow faster rate domestic market do medical stock interest check theseinvestor consider better rank stock same sector such edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
108,VAR,palo alto base lead manufacturer medical device software varian medical system inc var free report report adjust earning share third quarter fiscal steering past zack consensus estimate cent however adjust earning decline year year basis meanwhile revenue be year quarter constant currency cc revenue marginally miss zack consensus estimate varian medical report backlog end fiscal third quarter year year basis varian medical carry zack rank hold moment varian medical system inc price consensus ep surprise varian medical system inc price consensus ep surprise varian medical system inc quotesegment detailsoncology system segment revenue totale year year management oncology segment lack luster thank increase backlog mix emerge market notably cause longer backlog conversion cycle mar oncology revenue quarter review gross order quarter totale cc year quarter gross order increase cc emea apac gross order rise respectively year year basis particle therapy third quarter revenue segment be year year basis quarter company register order worth include order georgia proton therapy center atlanta segment put impressive show third quarter banking order single room probeam compact system university pennsylvania thailand product launch bode wellvarian medical have be take initiative gain customer attention broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna third quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt halycon receive clearance ce mark european directive allow varian medical start selling system management regulatory clearance china japan follow next year quarter varian medical book several order country australia belgium india morocco romania russia turkey marginsin third quarter gross margin expand basis point bps revenue buoy increase mix service consistent varian medical long term strategy oncology system gross margin rise nearly bps drive supply chain efficiency proton therapy gross margin third quarter remain flat year year basis revenue expense research development quarter be revenue meanwhile selling general administrative sg expense quarter be year year basis rise expense be drive investment new product launch fourth quarter management estimate adjust earning share range second fourth quarter varian medical expect revenue growth range earning band stock varian medical drop close follow earning release stock have gain last month compare favorably industry decline however current level be slightly lower gain same time frame key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
109,VAR,cerner corporation cern free report wholly own subsidiary cerner government service inc recently sign agreement department veteran affair va cerner aim facilitate care veteran community va efficient integrate network notably cerner government service provide industry lead solution digitize paper process hospital ambulatory practice public health correctional agency post announcement cerner share price inched close cerner be expect deliver exist healthcare solution senior citizen provide care giver crisp medical history single electronic health record ehr system be optimistic such development likely provide cushion stock have lose versus industry gain year time cerner have consistently prioritize health wellbeing age populace lately company also deploy technology department defense dod medical facility management latest move act catalyst public private health care sector furthermore cerner have be dominate headline bid digitize ehr system last report quarter company exist client continue migrate legacy system cerner millennium java cloud base automate library solution management cerner have bring hospital more ambulatory facility revenue cycle solution moreover company foresee significant growth opportunity ehr market statistic be more hospital ehr platform need be update future ehr platform evolutionof late cerner see slew development ehr platform recently georgia base crisp regional health inc deploy cerner ehr revenue cycle management solution facility view lend complete real time record individual heath additionally cerner ehr revenue cycle management solution be select indiana family social service administration fssa be integrate state run psychiatric facility market prospectsper study market market healthcare hcit market be expect reach cagr primary growth driver market be high return investment hcit solution government directive need curtail escalate healthcare cost zack rank key pickscerner carry zack rank sell better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
110,VAR,mechatronic high end technology incorporating electronic machine learn mechanical engineering have be vogue late grow prominence artificial intelligence ai robotic company organization significant exposure mechatronic have be rake huge profit research business wire decipher global mechatronic robotic market be project witness cagr period consider strong exposure mechatronic almost sphere technology automobile telecom more evolution medical mechatronic have be most fascinating grow prevalence minimally invasive robot assist surgery self automate home base care use information technology quick improve patient care well shift payment system value base model indicate predominance mechatronic medtech space so let delve detail medical mechatronic have be create new opportunity medtech raise investor confidence put money healthcare space long term gain be mechatronic shape healthcare paradigm medical mechatronic be much await digital evolution global healthcare industry medical mechatronic have provide innovation healthcare industry reduction size age old medical device development low cost disposable device portability device error free result hindawi renown healthcare engineering journal medical mechatronic revolution have be most important driver global knowledge base economy unite state here take look major aspect medical mechatronic have be do round global headline printing medical mechatronicsthe best example mechatronic healthcare industry be printing have change face medical device industry also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr major company stryker corporation syk free report have be early adopter printing technology company fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation robotic boost medical mechatronic rise mechatronic powerful compute improve sense molecular imaging have enabled new robotic solution mitigate age old problem medtech company solution be pain less error free inexpensive so medtech company be used mechatronic base robot cure disease have competitive edge strong customer base solid revenue handsome profit major company medtech giant intuitive surgical isrg free report be notable mention intuitive surgical design manufacture market da vinci surgical system advanced robot assist surgical platform mechatronic base platform enable minimally invasive surgery help avoid trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair day come let take look other medtech stock have be hog limelight base grow prevalence mechatronic artificial intelligence healthcare sector best medtech stock ride high mechatronicsin backdrop medtech stock be well position strong fundamental solid exposure mechatronic have used zack stock screener pick company have zack rank strong buy buy growth score research show stock growth score combine zack rank be better pick most abiom inc abmd free report stock sport zack rank growth score see complete list today zack rank stock here share abiom have surge year time compare favorably industry decline impella abiom flagship product line have continue be growth driver impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart expand flagship impella heart pump portfolio abiom recently announce receipt fda pre market approval pma impella cp heart pump smartassist april technology also feature optical sensor development have provide company significant exposure medical mechatronic company plan controlled roll technologically advanced heart pump hospital site develop heart recovery protocol next fiscal year varian medical system inc var free report stock have zack rank growth score share varian medical have gain year time varian medical have receive significant exposure medical mechatronic trend halcyon hyperarc platform halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt hyperarc platform be varian medical high definition radiotherapy technology apr varian medical launch halcyon kilovoltage imaging kv first human kv cone beam ct image halcyon be acquire washington university positive feedback image quality speed image acquisition process further varian medical hyperarc platform be design treat multiple metastase brain cancer case continue witness strong demand steris plc ste free report stock flaunt zack rank have growth score share steris have gain year time company manufacture market infection prevention decontamination microbial reduction surgical support product service steris acquisition base outsourced sterilization service provider synergy health plc be significant achievement buyout enabled combination steris infection prevention service business synergy hospital sterilization service today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
111,VAR,patterson company inc pdco free report underperform industry year time company share have lose versus industry increase current return be also lower index rise rapidly change healthcare environment unite state unfavorable price movement decline dental revenue integration risk significant challenge patterson company further management expect headwind technology equipment business persist fiscal patterson company have be shift new go market strategy expand technology base product portfolio currently company be also grapple legal issue zack consensus estimate bottom line decline last month show year year decline current quarter zack consensus estimate bottom line decline last month cent indicate fall year year basis patterson company inc price consensus patterson company inc price consensus patterson company inc stock have zack rank sell here take peek major issue plague patterson company dental product distribution industry be highly competitive majorly consist national regional local full service mail order distributor patterson company face competition national full service firm henry schein dental unit henry schein addition be least full service distributor operate regional level hundred small local distributor mandatory company constantly introduce product market tide competitive pressure failure do so dilute company market share dwindle dental sale third quarter fiscal reflect constant disruption company augmentation goal sale segment fall prior year quarter tally additionally patterson company sale consumable dental supply fall year year basis dental equipment sale also decline constant currency cc basis recent loss exclusive distribution right dentsply sirona have compel company shift new enterprise resource plan erp system efficiently manage inventory however system be create short term challenge undoubtedly termination contract present new opportunity patterson company expand distribution platform wider range product offering however company also witness heavy initial impact loss deal key picksa few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
112,VAR,bid strengthen medical management solution mms segment becton dickinson company bdx free report popularly know bd recently collaborate indiana base helmer scientific introduce refrigerate solution used bd new pyxis es refrigerator notably solution be first kind have be integrate automate dispense system post announcement new jersey base medical technology company share price drop marginal however past month bd rally impressive significantly outperform industry decline believe such favorable development provide cushion stock notably helmer scientific offer secure medical grade refrigerator freezer blood bank storage clinic lab pharmacy hospital research center university stock currently carry zack rank hold mms pyxis es system be significant contributor mms platform provide automate medication dispense system support decentralize medication management revenue last report quarter grow mms unit management upside be drive strong pyxis es adoption unite state well international growth come back news notification bd pyxis es be see bd healthsight viewer platform unique combination connective technology analytic expert service helmer access technology new bd pyxis es refrigerator provide storage refrigerate medication require temperature monitoring mms prospectsper research global medication management system market be expect reach value be poise see cagr period hence be conclude bd move have be timely strategic key picksa few better rank stock broader medical space be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
113,VAR,varian medical system inc var free report recently announce have receive regulatory clearance antitrust authority german federal cartel office fco acquisition sirtex medical limit bid become global leader multus disciplinary integrate cancer care solution varian medical sign agreement acquire australia base global life science company onjan favorable price performanceover past year varian medical outperformed industry term price performance company share have return compare favorably industry rally also current return be higher index gain strong revenue various oncology imaging component product focus inorganic growth strong overseas presence emerge country be positive deal transaction be expect strengthen varian medical footprint australia close acquisition be accretive earning share first fiscal close transaction acquisition be likely provide customer wider range cancer care solution deal be expect expand varian medical addressable market interventional oncology management varian leverage capability treatment plan delivery image guidance process oncology practice management software radiation safety unit sirtex interventional oncology platform sirtex be global leader focus interventional oncology therapy company have distribution operation unite state europe asia regulatory approvalvarian medical get early termination wait period hart scott rodino antitrust improvement act deal act company be not permit complete schedule merger acquisition transfer security asset have make detailed filing federal trade commission department justice further company ensure transaction not affect commerce current antitrust law german fco also approve propose acquisition confirm do not violate act restraint competition oncology segment get boostvarian medical oncology segment apac be likely get boost post deal closure oncology system be varian medical largest operate business segment last quarter net oncology revenue totale year year basis gross order be year quarter apac gross order increase year year strong order growth greater china japan operate earning segment rise market potentialper research market global oncology market be estimate witness cagr international emerge market be equip address grow incidence cancer company strong overseas presence enable cash opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly australia be grow faster rate domestic market however company face stiff competition accuray incorporate aray free report oncology technology space zack rank other stock considervarian medical have zack rank buy other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
114,VAR,second quarter earning season commence last week index have good start respect earning revenue growth latest earning preview jul member total market cap have report quarterly number total earning member have go higher revenue week member be line report quarterly result time be bullish equity market be gradually demonstrate sequential improvement store medical space overall growth be steadily accelerate few precede quarters performance investor be concern healthcare space sector have be see struggle lot past half year thank political power change ongoing policy restructure related battle president donald trump finally amend earlier propose american health care act ahca totally repeal replace obamacare uncertainty medical space be towering high investor be currently adopt see policy space lack visibility befuddle bullish trend medical sector broader zack sector be maintain past few quarters accordingly second quarter expect earning growth rate stand break even level revenue growth projection compare unfavorably first quarter report earning growth rate revenue growth let take sneak peek performance major medical instrument company broader medical space expect jul edward lifescience corporation ew free report lead cardiovascular product maker be schedule report second quarter result market close jul edward lifescience post strong global sale last report quarter primarily buoy strength transcatheter heart valve tavr banking continue therapy adoption geography notable strength company be expect maintain bullish trend second quarter well edward lifescience currently carry zack rank buy have earning esp be most accurate estimate zack consensus estimate be par cent note positive zack esp serve lead indicator likely positive earning surprise bullish zack rank increase predictive power esp read more edward lifescience earning surprise store edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotethermo fisher scientific inc tmo free report base medical instrument manufacturer focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result second quarter company have already spend research development same trend be expect year too thermo fisher be expect beat expectation report second quarter result market open have right combination key ingredient stock currently carry zack rank buy have earning esp be most accurate estimate be zack consensus estimate be lower uncover best stock buy sell re report earning esp filter read more thermo fisher earning surpass expectation thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotevarian medical system inc var free report lead provider radiotherapy radiosurgery proton therapy brachytherapy treat cancer be schedule report third quarter fiscal earning market close strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient proven model do not conclusively show varian medical be likely beat earning quarter varian currently carry zack rank hold have earning esp be most accurate estimate zack consensus estimate be par cent see complete list today zack rank stock here read more varian medical earning be surprise store varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
115,VAR,varian medical system inc var free report be schedule report third quarter fiscal earning jul market close last quarter company report earning cent share beat zack consensus estimate penny however adjust earning decline year year basis factor playwe be particularly upbeat varian oncology business account company total revenue second quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space third quarter fiscal varian expect adjust earning share range cent cent revenue be expect increase year year basis further strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc apart varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open new office africa middle east show be aware opportunity region moreover varian strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
116,VAR,abiom inc abmd free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock therefore time advantage stock price appreciation earning report abiom stock have rally further share have rise whopping significantly outperform industry decline year time current level be also higher index return last day zack consensus estimate earning rise cent company have zack rank strong buy indicate possibility outperformance term furthermore stock have growth score research show stock growth score combine zack rank buy be better pick most let find bullish trend sustain stock impressive performance long run make attractive benchmarkabiom recently joined coveted benchmark replace wyndham worldwide corp abiom currently have market capitalization cement position further company strong fundamental adequate liquidity reasonable price sector representation have lend competitive edge medtech industry read more abiom replace wyndham benchmark impella solid driverabiom flagship product line impella continue be growth driver last report quarter company witness increase adoption impella product unite state germany japan company flagship impella rp have see launch new site introduction recently impella be used treat year old cardiac patient mitsui memorial hospital lead cardiovascular center japan abiom recently announce receipt fda pre market approval smartassist moreover recent ce mark impella europe enhance product line significantly enabled company advance field heart recovery fy view fiscal company expect total revenue range reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range full year tax rate be expect other key pickssome other top rank medical stock be varian medical var free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
117,VAR,accuray inc aray free report underperform industry last month company share have lose wider industry fall current return also compare unfavorably index rise regulatory issue regard onrad intense competition radiation oncology market sluggish macro economic condition unfavorable foreign exchange rate be significant challenge company zack consensus estimate bottom line be peg loss cent notably have widen cent last month zack consensus estimate current quarter be peg loss cent stock have zack rank sell here take peek major issue plague accuray accuray incorporate price consensus accuray incorporate price consensus accuray incorporate quoteissue regard onradonrad be accuray flagship product value segment medtech market fact company have be try build solid sale channel important segment long however order uptake onrad be somewhat dampen lack regulatory movement china recently company have be face headwind order perspective due continue class license delay region end third quarter fiscal accuray announce distributor have be work hard position onrad value segment year cutthroat competition niche marketsaccuray be expose significant competition radiation oncology market be characterize rapid technological change company compete head head varian medical system inc var free report elekta ab mitsubishi heavy industry viewray brainlab ag market cyberknife system face stiff challenge varian medical trilogysystem tomotherapy system face competition rapidarc technology truebeam system forex woesa percentage total sale international sale have increase significantly last year accuray significant international presence augment customer base however fluctuation currency exchange rate particularly strong dollar continue adversely impact company backlog top line growth further key picksa few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate flaunt zack rank varian medical have project long term growth rate stock carry zack rank buy hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
118,VAR,mckesson corporation mck free report recently complete previously announce acquisition medical specialty distributor msd value deal be part continue effort mckesson management respond change healthcare supply device distribution further complement mckesson exist low cost site care infusion platform deal be initiate new york base new mountain capital agree sell msd mckesson corporation new mountain ownership msd enterprise value approximately triple prove be accretive mckesson earning long term notably msd be medical supply equipment distributor base stoughton company serve diversify long tenured customer base site nationwide msd establish offer provider home infusion market well technology service patient enable mckesson provide incremental service other customer segment furthermore mckesson recently announce multus year strategic growth initiative provide enhance solution rapidly grow specialty pharmaceutical market price performancewe believe development such provide cushion mckesson share have decline compare industry gain year time market prospect lucrativeper market research global home healthcare market be value be expect generate revenue grow cagr hence be conclude mckesson move have be timely strategic mckesson acquisition have be actively pursue acquisition drive inorganic growth lately company complete acquisition rxcrossroad cvs health transaction worth management rxcrossroad acquisition have expand company broad range solution lifecycle drug biopharma company also support manufacturer program specialty solution additionally recent past company acquire covermymed electronic prior authorization solution provider pharmacy company have also be work integrate rexall other recent acquisition be expect drive earning zack rank key picksmckesson currently carry zack rank hold few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate flaunt zack rank varian medical have project long term growth rate stock carry zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target mckesson corporation mck free report recently complete previously announce acquisition medical specialty distributor msd value deal be part continue effort mckesson management respond change healthcare supply device distribution further complement mckesson exist low cost site care infusion platform deal be initiate new york base new mountain capital agree sell msd mckesson corporation new mountain ownership msd enterprise value approximately triple prove be accretive mckesson earning long term notably msd be medical supply equipment distributor base stoughton company serve diversify long tenured customer base site nationwide msd establish offer provider home infusion market well technology service patient enable mckesson provide incremental service other customer segment furthermore mckesson recently announce multus year strategic growth initiative provide enhance solution rapidly grow specialty pharmaceutical market price performance believe development such provide cushion mckesson share have decline compare industry gain year time market prospect lucrative market research global home healthcare market be value be expect generate revenue grow cagr hence be conclude mckesson move have be timely strategic mckesson acquisition portfolio mckesson have be actively pursue acquisition drive inorganic growth lately company complete acquisition rxcrossroad cvs health transaction worth management rxcrossroad acquisition have expand company broad range solution lifecycle drug biopharma company also support manufacturer program specialty solution additionally recent past company acquire covermymed electronic prior authorization solution provider pharmacy company have also be work integrate rexall other recent acquisition be expect drive earning zack rank key pick mckesson currently carry zack rank hold few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate flaunt zack rank varian medical have project long term growth rate stock carry zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
119,VAR,share abaxis inc abax free report sky-rocket soon acquisition news grab headline stock jump more yesterday follow animal health company zoetis inc zts free report announcement buy abaxis approximate deal value deal glancezoetis have make cash offer share abaxis shareholder be premium close abaxis share price denote price just news release banking exciting deal share abaxis rise wednesday reflect time high company later close price higher offer value abaxis inc price abaxis inc price abaxis inc quote transaction be expect complete end subject customary close condition regulatory approval abaxis stakeholder consent expect synergy adoption abaxis point care diagnostic instrument zoetis expect consolidated company veterinary diagnostic category grow faster animal health industry management integration bring significant synergy benefit company abaxis state have recently invest expand operation europe latin america asia pacific region revenue expect be draw internationally fiscal meanwhile zoetis already have substantial global presence direct veterinary customer relationship deliver greater value more customer worldwide undoubtedly buyout accelerate growth combine entity overseas business market market report veterinary diagnostic market be anticipate witness cagr reach value financial impact acquisition adjust basis zoetis do not expect immediate material impact merged company earning transaction be however likely be accretive bottom line share price performancein past month abaxis share have rally outperform industry gain zack rank key picksabaxis currently carry zack rank hold better rank stock broader medical space be genomic health inc ghdx free report varian medical system inc var free report genomic health have expect growth rate stock sport zack rank strong buy see complete list today zack rank stock here varian medical have project long term growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
120,VAR,cerner corporation cern free report integrate electronic health record ehr revenue cycle management solution have be recently picked crisp regional health inc post announcement cerner stock rally however cerner currently carry zack rank strong sell believe latest development provide cushion cerner share have lose industry rally year time collaboration be expect provide cerner platform connect community healthcare technology apart expand foothold healthcare hcit space get back news crisp regional be georgia base healthcare center provide comprehensive network health social service facility crisp regional adapt cerner millennium platform design provide complete real time view individual heath be support cerner communitywork cloud base platform provide integrate digital record patient health history moreover patient family be able safely communicate doctor schedule appointment access health history furthermore cerner revenue cycle solution allow clinician access patient clinical financial datum cerner field healthcare be currently witness rise use analytic meanwhile cerner have be dominate headline courtesy effort digitize ehr system notably cerner healtheintent be big datum platform provide company significant exposure ai artificial intelligence trend medtech industry cerner millennium be java cloud base automate library solution suitable small midsize medical practice last report quarter cerner exist client continue migrate legacy system cerner millennium management hospital more ambulatory facility have choose cerner revenue cycle solution moreover company foresee significant growth opportunity ehr market management be more hospital ehr platform need be update future latest development ehr platform cerner recently collaborate uniform datum system medical rehabilitation udsmr view transmit inpatient rehabilitation facility patient assessment instrument irf pai datum functional independence measure fim score directly udsmr prevent manual export import datum additionally cerner ehr revenue cycle management solution be recently select indiana family social service administration fssa be integrate state run psychiatric facility market prospectsper study market market healthcare market be expect reach cagr primary growth driver market be high return investment hcit solution government directive need curtail escalate healthcare cost key pickssome better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have estimate long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate stock flaunt zack rank varian medical have project long term growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
121,VAR,bid replace simple custom make datum warehouse unique industry specific datum model veeva system veev free report recently introduce veeva nitro new model commercial datum warehouse life science veeva nitro be build amazon redshift fast query performance largest datum set new model unify important datum source prescription sale formulary establish solid commercial datum foundation boost artificial intelligence ai analytic medtech industry management veeva nitro cater organization unique regional requirement include specialize datum source business process datum model be base deep industry base leverage company flagship veeva crm suite veeva vault promo mat veeva system inc price veeva system inc price veeva system inc quote further veeva nitro provide business intelligence ai tool deliver tailor datum visualization veeva crm myinsight veeva system commercial excellence integrate master datum compliant commercial content multichannel crm collaboration sponsor cro well site provide competitive edge medtech space conclusion veeva system have be undertaking consistent effort support industry collaboration life science be do launch new product market easily be encourage veeva system consistent effort product innovation launch grow global demand cloud base vault application also boost opportunity veeva system product release industry focuse approach bode well veeva system share have outperformed industry year time stock have gain compare industry rally company have zack rank hold stock considera few better rank stock broader medical space be abiom inc abmd genomic health inc ghdx varian medical system inc var abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate stock flaunt zack rank varian medical have project long term growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
122,VAR,have be pay attention share surmodic srdx free report share have be move stock past month srdx hit new week high previous session surmodic have gain start year compare move medical sector year date return peer group drive outperformance stock have impressive record positive earning surprise have beaten zack consensus estimate last quarters last earning report surmodic report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year surmodic be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricssurmodic be week high right now future hold srdx key aspect question be take look valuation metric order determine company be due pullback level front look zack style score give investor variety way comb stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style surmodic have value score stock growth momentum score be respectively give company vgm score surmodic inc price consensus surmodic inc price consensus surmodic inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately surmodic currently have zack rank buy thank favorable earning estimate revision cover analyst recommend investor select stock carry zack rank strong buy style score look surmodic fit bill thus seem srdx share still be poise more gain ahead do surmodic stack competition share surmodic have be move higher company still appear be decent choice rest industry industry peer be also solid potential pick include baxter international bax free report steris plc ste free report varian medical system var free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news surmodic still fundamental srdx be promising still have potential be week high
123,VAR,varian medical system inc var free report be currently top perform stock medtech space company broad product spectrum strong second quarter fiscal result solid international foothold deserve mention company have positive average earning surprise trail quarters last day estimate have moved north change zack consensus estimate earning past month share varian medical have gain industry decline current level be also higher return let take look zack rank buy company make tempting addition portfolio now invest strong resultsvarian medical post stellar second quarter fiscal result earning revenue surpass respective zack consensus estimate earning improve year year basis revenue rise year company flagship halcyon platform majorly drive revenue quarter inception halcyon receive order reflect strong demand platform growth oncology segment also drive revenue gross order totale report quarter product portfolio solidvarian medical have be gain diversify gamut product halcyon radiotherapy treatment system be note design offer cost effective cancer care notably platform have receive clearance ce mark european directive allow varian medical start selling system unite state recently varian medical have new imaging technology halcyon treatment system expand capability ability deliver high quality cancer care globally radiotherapy hyperarc platform high definition radiotherapy technology deserve special mention be design treat multiple metastase brain cancer case have see robust demand so far recently company launch new version exist velocity software solution include rapidsphere module selective internal radiation therapy sirt dosimetry analysis enable cancer care team perceive tumor response normal tissue toxicity individual patient receive sirt global footholdvarian medical foresee substantial opportunity cancer care emerge market second quarter asia pacific revenue grow year year greater china maintain growth quarter japan have also be profitable space varian medical moreover europe middle east india africa geography revenue grow significantly company have also expand reach strategic overseas buyout recently varian medical sign agreement acquire sirtex australian base company focuse interventional oncology therapy additionally cooperative cl enterprise lead distributor radiotherapy equipment taiwan have be acquire varian medical other key picksother top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report exelixis inc exel free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate current quarter stock sport zack rank exelixis have project growth rate current quarter stock sport zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
124,VAR,dentsply sirona inc xray free report report adjust earning share ep cent first quarter beating zack consensus estimate however metric fall year year net sale increase year year also figure surpass zack consensus estimate however metric decline constant currency cc exchange rate stock carry zack rank hold dentsply price movement have be unfavorable past year stock have lose compare unfavorably industry rise net sale exclude precious metal impact net sale company precious metal dental alloy product be used third party construct crown bridge material be subject risk fluctuation precious metal price avoid impact fluctuate price dentsply report net sale precious metal content show actual performance independent precious metal price volatility net sale segment be year year dentsply sirona inc price consensus ep surprise dentsply sirona inc price consensus ep surprise dentsply sirona inc quotesegmental business be organized report segment dental healthcare consumable technology dental healthcare segment comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product net sale improve segment decline cc technology equipment consist dental implant cad cam system imaging system treatment center orthodontic product metric increase segment year year basis however revenue be cc geographic detailsin quarter sale unite state fall year year revenue area fall cc net sale europe increase cc net sale rest world climb cc margin profit report quarter be year year however percentage revenue gross margin contract basis point bps operate income fall quarter operate margin quarter contract bps net revenue guidance management expect adjust earning share range previous range notably zack consensus estimate earning be currently peg share significantly higher management expectation revenue be project rise cc zack consensus estimate revenue be currently peg exit first quarter solid note beating zack consensus estimate count robust performance company flagship dental implant cad cam system imaging system treatment center orthodontic product platform hold considerable promise long haul emerge market asia pacific middle east offer healthy growth opportunity long term basis remain vastly untapped low dental product penetration company agreement medtech bigwig patterson company canada be likely drive sale dentsply recently witness rebound sale asia particularly japan strong growth russia flip side lower guidance be indicative loom concern company higher capital expenditure product development tough competition be expect exert pressure margin unfavorable foreign exchange rate integration risk be major headwind term earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
125,VAR,have be pay attention share idexx laboratory idxx free report share have be move stock past month idxx hit new week high previous session idexx laboratory have gain start year compare move medical sector year date return peer group drive outperformance stock have great record positive earning surprise have beaten zack consensus estimate last quarters last earning report idexx laboratory report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year idexx laboratory be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricsidexx laboratory be week high right now future hold idxx key aspect question be take look valuation metric order determine company be due pullback level front look zack style score give investor variety way comb stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style idexx laboratory have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately idexx laboratory currently have zack rank buy thank rise earning estimate recommend investor select stock carry zack rank strong buy style score look idexx laboratory pass test thus seem idxx share have bit more room run term do idexx laboratory stack competition share idexx laboratory have be move higher company still appear be decent choice rest industry industry peer be also look good include iradime irmd free report integer holding itgr free report varian medical system var free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news idexx laboratory still fundamental idxx be promising still have potential be week high
126,VAR,month have go last earning report varian medical system inc var free report share have lose time frame underperform market recent negative trend continue lead next earning release be var due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningsvarian medical report first quarter fiscal adjust earning share beat zack consensus estimate cent adjust earning also improve year year basis revenue totale beat zack consensus estimate year year basis revenue increase company have strengthen foothold radiation therapy market grow order basis trail month segment detailsoncology system say quarter oncology revenue totale year year basis gross order be year quarter gross order americas inched yearly basis emea gross order rise year year apac gross order increase year year strong order growth greater china japan operate earning segment rise particle therapy revenue segment decline year year basis however company book new proton order university alabama birmingham sylvester comprehensive cancer center university miami company install varian probeam compact single room proton therapy system new university alabama birmingham proton therapy center additionally company also provide aria information management system eclipse treatment plan system hyperarc halcyon drive high definition radiotherapy technology continue gain prominence platform witness new order more order be upgrade notably hyperarc be design treat multiple metastase brain cancer case continue witness strong demand number unique varian software customer grow first quarter install basis rapidplan double velocity also grow high double digit revenue service grow oncology business include performance obligation installation training warranty first quarter halcyon platform witness total order inception reflect solid demand platform quarters ahead anticipate growth be drive solid new scale configuration optimized different customer segment advanced capability marginsgross margin report quarter be expand basis point bps year year basis operate margin be expand bps year year basis oncology gross margin be bps particle therapy gross margin be quarter due mix lower margin deal financial company exit first quarter cash cash equivalent debt moreover cash flow operation be fy company expect revenue range adjust earning share be expect band cash flow operation be project range have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter past month consensus estimate have shift due change varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotevgm scoresat time var have great growth score be lag lot momentum front stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable growth investor momentum investor outlookestimate have be trend upward stock magnitude revision look promising notably var have zack rank hold expect line return stock next few month
127,VAR,cardinal health inc cah free report report third quarter fiscal adjust earning share miss zack consensus estimate adjust earning fall year year revenue increase year year basis almost edge past zack consensus estimate cardinal health have zack rank hold last month share cardinal health have outperformed industry stock have return industry rise segmental revenue increase year year basis segment witness strong growth specialty business gain large number pharmaceutical distribution customer however segment witness expiration large mail order customer contract divestiture company china distribution business pharmaceutical witness decline profit thank generic pharmaceutical pricing medical segmentrevenue segment improve primarily higher contribution new exist customer acquisition patient recovery business medical segment profit increase cardinal health inc price consensus ep surprise cardinal health inc price consensus ep surprise cardinal health inc quotemargin profit increase year year percentage revenue gross margin expand basis point bps net revenue company slash guidance fiscal adjust earning share current range be significantly lower previous estimate downside be cause company effective tax rate associate cordis business zack consensus estimate revenue be peg takecardinal health exit quarter tepid note adjust earning miss consensus mark company witness encourage performance medical segment pharmaceutical segment register strong growth specialty business gain large number pharmaceutical distribution customer further company be banking strategic buyout joint venture supply agreement drive growth growth business profit pharmaceutical segment be hurt generic pharmaceutical pricing huge investment pharmaceutical platform lackluster generic performance be likely mar cardinal health operational efficiency upcoming quarters intense competition customer concentration be other bottleneck recently company close divestiture cardinal health china distribution earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
128,VAR,express script hold company esrx free report post first quarter adjust earning share beat zack consensus estimate penny further adjust earning improve year year revenue edge past zack consensus estimate inched year year upside be drive operational cost improvement backed focus technology digital tool home delivery specialty service stock have zack rank sell express script have outperformed industry year time stock have gain period compare industry rise patient claim volume script first quarter witness year year decline patient claim adjust network claim be year year adjust home delivery specialty claim be report quarter year year result net adjust claim first quarter be year year basis decline be primarily drive loss certain public sector client express script hold company price consensus ep surprise express script hold company price consensus ep surprise express script hold company quote margin detailsadjust gross profit first quarter be year year percentage revenue adjust gross margin be flat year year adjust selling general administrative expense be prior year quarter express script get medical care pharmacy benefit roof express script recently announce be get acquire cigna corporation global health insurance company acquisition be expect be conclude dec cigna take express script cash stock transaction worth term deal cigna pay cash share stock newly combine company closure express script shareholder own approximately combine company transaction result total cost synergy guidanceadjust earning share second quarter be estimate range represent growth year year notably zack consensus estimate earning be currently peg be project range company expect total adjust claim second quarter range be attributable core business adjust earning be estimate band significantly previous range share be suspension share repurchase program notably zack consensus estimate earning be currently peged lie significantly guidance revenue be expect band zack consensus estimate revenue be currently peg lie guidance adjust ebitda be expect script end first quarter strong note beating consensus mark count however lackluster guidance be indicate concern stock moreover company face stiff competition raise concern buoy strong result quarter express script enterprise value initiative be estimate range notably management expect cumulative saving nearly earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
129,VAR,cerner corporation cern free report report adjust first quarter earning cent share year quarter figure be line zack consensus estimate revenue rise year year miss zack consensus estimate stock have zack rank hold cerner underperform industry year time stock have lose compare industry return booking year year upside revenue be primarily attribute increase booking first quarter booking be year year basis company register strong booking business office service however subscription booking be lower expect cerner corporation price consensus cerner corporation price consensus cerner corporation quotesegment detailsinstead report revenue category system sale support maintenance service cerner report segment first quarter license software first quarter fall year year basis lower expect subscription booking mar growth segment subscription account revenue worth year year basis professional service increase year year management strong performance segment be likely enhance revenue cycle position manage service segment revenue be year year support maintenance revenue be year year reimburse travel sale amount year quarter marginsgross margin first quarter be almost flat year year operate margin report quarter be contract basis point bps year year basis downside be cause surge operate expense rise year year growth be drive personnel expense related revenue generate associate cash item financial positioncerner exit first quarter free cash flow operate cash flow totale long term debt include capital lease obligation be slightly sequential basis view downbeatcerner expect second quarter revenue zack consensus estimate same be higher project range second quarter adjust earning share be project range cent range be lower zack consensus estimate cent revenue be project range range zack consensus estimate same be significantly higher projection full year adjust earning share be estimate range lag zack consensus estimate further company expect second quarter new business booking range exit first quarter tepid note miss consensus mark top line front revenue come expectation due software issue technology resale lesser expect subscription booking delay va contract downbeat guidance indicate concern stock further lower margin technology resale result higher mix device resale be concern additionally cerner have be face macroeconomic challenge cutthroat competition niche space surge operate expense also add wo international growth be likely boost company prospect australia canada middle east ireland germany cerner witness strong cash flow record booking believe company have growth opportunity revenue cycle management rcm population health ambulatory market base product strength enviable track record add new client solid growth healtheintent platform also hold promise further company recently report suite development ehr platform earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
130,VAR,bid overhaul oncology system segment varian medical system inc var free report recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company deal be initiate last september varian have state utilize evinance patented technology offer better service client cds provide physician patient latest clinical information comprise variety tool enhance evidence base decision make clinical enhance quality care patient undergo cancer diagnosis rationale dealmerge evinance platform oncology provide visual care pathway compliance tracking base national comprehensive cancer network nccn turn help meet varian long term target consolidate company foot provide multus disciplinary integrate cancer care solution acquisition be likely diversify company oncology system business integrate clinical decision support adherence tracking deliver comprehensive cancer care varian medical system inc price consensus varian medical system inc price consensus varian medical system inc provide clinician platform visualize patient journey apply evidence base guideline recent development oncologyvarian aria oncology information system have receive office national coordinator health information technology onc health certification group llc authorize certification body abc abc have be empower test software compliance requirement federal government program notably certification follow testing aria software comply applicable standard certification criterium department health human service hhs market prospectsper survey transparency market research tmr global companion diagnostic test oncology market be expect value end market be project grow cagr rise demand personalize healthcare target therapy have escalate growth global companion diagnostic test market consider solid prospect varian latest development oncology segment buoy optimism be also line company effort establish premier cancer care provider price performanceover past year varian have outperformed broader industry term price stock have appreciate compare growth record industry zack rank stock considervarian carry zack rank hold better rank stock broader medical space be centene corporation cnc free report bioverativ inc athenahealth inc athn free report stock sport zack rank strong buy see complete list today zack rank stock here centene project long term growth rate be stock have rally past month bioverativ have expect long term growth rate stock have surge whopping month time athenahealth have expect long term growth rate stock have gain past month zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
131,VAR,abiom inc abmd free report be schedule join coveted benchmark market open company be currently part midcap index index be periodically remove stock have be acquire other company delist stock exchange fail meet mandatory criterium index consequently other company meet criterium be add list replacement delete stock notably abiom be replace wyndham worldwide corp index company be add global industry classification standard gic health care supply sub industry index benefit abiom portfolio lead company have approximately coverage available market capitalization index be important metric equity company reserve forte stature have market capitalization more abiom currently have market capitalization further company financial viability adequate liquidity reasonable price sector representation have lend competitive edge medtech industry believe news provide solid boost abiom shareholder have successfully meet inclusion criteria join list company share have outperformed index year time stock have return significantly higher rise share be expect move higher abiom latest development indicate probability company penetration prophylactic high risk pci cardiogenic shock patient market key factor drive abiomedimpella abiom flagship product line have continue be key growth driver impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart recently impella be used successfully treat year old cardiac patient mitsui memorial hospital lead cardiovascular center japan such incident elucidate strong clinical demand impella overseas additionally install customer base impella cp heart pump grow new hospital take total count impella cp site install customer base impella heart pump grow new hospital take total number impella site further abiom open new site impella rp total hospital set record patient support report quarter advisory board independent expert healthcare consultant company acquire unite healthcare circulate additional publication reference impella broaden flagship impella heart pump portfolio abiom recently announce receipt fda pre market approval pma smartassist also feature optical sensor april company plan controlled roll technologically advanced heart pump hospital site develop heart recovery protocol next fiscal year recent ce mark impella europe enhance product line significantly enabled company advance field heart recovery recently report fourth quarter impella heart pump garner worldwide revenue worth year year unite state impella rake year quarter level internationally revenue generate impella heart pump be whopping lucrative market trend coronary heart diseaseswe believe abiom continue benefit rise number patient suffering coronary heart disease chd unite state datum available center disease control prevention cdc chd be most common type heart disease claim approximately life annually importantly unite state bear year chd include cost health care service medication lose productivity abiom product line focus procedure offer device be minimally invasive help patient overcome trauma open surgery company product be become increasingly popular lower patient recovery time save hospitalization cost estimate move upbuoyed favorable tiding zack consensus estimate current quarter earning have inched cent share month time full year zack consensus estimate rise abiom inc price consensus abiom inc price consensus abiom inc stock flaunt zack rank strong buy see complete list today zack rank stock here other key picksa few other top rank stock broader medical space be genomic health inc ghdx free report varian medical system inc var free report genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
132,VAR,maintain streak positive earning surprise varian medical system inc var free report report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis revenue totale beat zack consensus estimate year year basis revenue rise cc company strengthen foothold radiation therapy market grow order basis trail month varian have zack rank buy company have outperformed industry year time stock have return compare favorably industry rise let delve deeper company quarterly result segment detailsoncology systemsin second quarter oncology revenue totale cc year year basis varian medical worldwide net install base be unit unit year year basis whole gross order be year quarter cc gross order americas inched year year basis cc emea gross order be flat year year apac gross order inched year year operate earning segment rise year year february varian medical acquire small privately hold quality assurance software company mobius medical system management mobius market lead software doselab be solid enhancement varian medical exist portfolio patient treatment plan qa machine qa technology strong performance software hardware service revenue boost varian medical oncology system second quarter particle therapyrevenue segment inched year year basis notably company do not book new probeam order quarter march varian medical announce first patient treatment st petersburg proton therapy center russia important step expand access proton therapy world varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quote halcyon drive revenuesin second quarter halcyon platform witness total order inception majority greenfield site reflect solid demand platform quarters ahead project growth be drive solid new scale configuration optimized different customer segment advanced capability marginstotal company gross profit report quarter be year year gross margin report quarter be expand basis point bps year year basis oncology gross margin report quarter be percentage revenue bps be primarily drive revenue growth hardware software service well margin rate expansion europe pricing discipline ongoing operational excellence financial company end quarter cash cash equivalent debt cash flow operation be year year drive operate income performance work capital efficiency guidance revenue growth be expect range year year basis fiscal zack consensus estimate revenue be peg moment adjust operate earning percentage revenue be expect range adjust earning share be expect range zack consensus estimate earning be peg moment cash flow operation be expect range medical end second quarter solid note halcyon platform drive top line solid revenue oncology grow adoption particle therapy strong overseas presence particularly emerge country be positive varian medical sign agreement acquire sirtex australian base company focuse interventional oncology therapy approximately aud varian oncology care management platform company acquire evinance innovation small privately hold montreal base company specialize clinical decision support software solid guidance fiscal instill confidence stock flip side company do not book new order proton therapy unit company compete large electronic company well smaller more specialize radiation therapy equipment manufacturer thus competition be likely mar revenue earning medtech major glancea few other top rank stock medical space report impressive result earning season be laboratory corporation america holding lh free report cheme corp che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here labcorp report first quarter adjust earning share beating zack consensus estimate revenue come exceed zack consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
133,VAR,first quarter earning season see starry start most member beating earning maintain revenue momentum apr however number positive revenue surprise be lag precede year number be par sequential figure latest earning preview total earning company have report so far be year year higher revenue total beat earning surpass revenue estimate week member be line release quarterly result expect get clearer picture first quarter earning season have offing end week medical sector snapshotmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model broadly speaking latest tax cut job act many other change slash corporate tax rate earlier have also buoy optimism inventor medical product space be part broader medical sector have be hog lot limelight certain favorable development consider favorable demographic change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector have be go strong further senate decision defer implementation industry wide excise tax couple year know medical device tax have instilled confidence investor tax be put effect jan bill also delay so call cadillac tax tax employer insurance moreover medtech company have be ride high innovation grow consolidation focus emerge market backdrop let take look major medical product stock schedule release result apr quantitative zack model stock advantageous combination solid zack rank strong buy buy hold positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filter laboratory corporation america holding lh free report labcorp first quarter result be expect reflect gain strong labcorp diagnostic segment favorable price mix tuck acquisition organic volume zack consensus estimate earning be peg indicate year year growth further predict earning beat quarter labcorp have zack rank earning esp read more launchpad aid labcorp covance arm earning see complete list today zack rank stock here stock surpass zack consensus estimate trail quarters average beat reflect chart laboratory corporation america holding price ep surprise laboratory corporation america holding price ep surprise laboratory corporation america holding quotethermo fisher scientific inc tmo free report have be progress well analytical instrument business rise global demand company focus growth implementation strategy consolidation product offering be encourage initiative be likely reflect first quarter result zack consensus estimate earning be peg show year year growth however be difficult conclusively predict earning beat thermo fisher have zack rank earning esp read more offing thermo fisher earning stock surpass zack consensus estimate last quarters average beat be see chart thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quoteboston scientific corporation bsx free report have be gradually witness improve performance interventional cardiology ic lead innovative portfolio efficient commercial team globally watchman platform be set see stellar first quarter consistent global momentum boston scientific effort continue drive growth zack consensus estimate be peg cent indicate year year growth model show earning beat boston scientific have zack rank earning esp read more watchman aid boston scientific earning wo stock beat zack consensus estimate trail quarters average beat be negative show chart boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotealign technology inc algn free report first quarter result be likely reflect gain continue adoption invisalign technology strong scanner service business zack consensus estimate earning be peg cent reflect year year improvement foresee beat align technology have zack rank earning esp read more steady overall growth drive align earning stock trump zack consensus estimate trail quarters average beat be see chart align technology inc price ep surprise align technology inc price ep surprise align technology inc quotevarian medical system inc var free report favorable revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence be likely have influenced company second quarter fiscal result zack consensus estimate earning be pin highlight year year rise however don see beat varian have zack rank earning esp read more varian medical earning be surprise store stock beat zack consensus estimate trail quarters average beat demonstrated chart varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
134,VAR,varian medical system inc var free report be schedule report second quarter fiscal earning apr market close favorable revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence be likely drive company second quarter fiscal earning last quarter company deliver adjust earning share beat zack consensus estimate cent adjust earning also improve year year basis revenue totale beat zack consensus estimate second quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate adjust earning be peg share indicate increase year year varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quote let delve factor be likely impact varian medical upcoming quarterly result factor playoncology drive growth be upbeat varian medical oncology business account company total revenue last quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have be winning international contract oncology space bid overhaul oncology system segment varian medical recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company deal be initiate september company have state utilize evinance patented technology offer better service client mar varian medical announce st petersburg center nuclear medicine successfully complete first pediatric patient treatment varian probeam proton therapy system product launch successful launch halcyon therapy system deserve mention regard varian medical have be undertaking initiative attract customer broad spectrum product recently company unveil halcyon radiotherapy treatment system recently first quarter fiscal halcyon platform witness order inception reflect solid demand platform quarters ahead jan varian medical announce halcyon system have receive taiwan fda approval allow company market new cancer treatment system country feb varian medical announce halcyon cancer treatment platform receive atomic energy regulatory board aerb certificate import supply india company expect revenue range adjust earning share be expect band cash flow operation be project range cut throat competition varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer elekta accuray emerge proton therapy market company face competition hitachi ion beam application mevion medical system sumitomo intense competition be anticipate increase expenditure nascent proton therapy market dent margin moreover pricing pressure traditional radiotherapy be major concern earning whispersour proven model do not show earning beat varian medical quarter be stock need have positive earning zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank abbott laboratory free report have earning esp zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
135,VAR,varian medical system var free report report first quarter fiscal adjust earning share beat zack consensus estimate cent adjust earning also improve year year basis revenue totale beat zack consensus estimate year year basis revenue increase company have strengthen foothold radiation therapy market grow order basis trail month varian medical system inc price consensus ep surprise varian medical system inc price consensus ep surprise varian medical system inc quote segment detailsoncology system say quarter oncology revenue totale year year basis gross order be year quarter gross order americas inched yearly basis emea gross order rise year year apac gross order increase year year strong order growth greater china japan operate earning segment rise particle therapy revenue segment decline year year basis however company book new proton order university alabama birmingham sylvester comprehensive cancer center university miami company install varian probeam compact single room proton therapy system new university alabama birmingham proton therapy center additionally company also provide aria information management system eclipse treatment plan system hyperarc halcyon drive high definition radiotherapy technology continue gain prominence platform witness new order more order be upgrade notably hyperarc be design treat multiple metastase brain cancer case continue witness strong demand number unique varian software customer grow first quarter install basis rapidplan double velocity also grow high double digit revenue service grow oncology business include performance obligation installation training warranty first quarter halcyon platform witness total order inception reflect solid demand platform quarters ahead anticipate growth be drive solid new scale configuration optimized different customer segment advanced capability marginsgross margin report quarter be expand basis point bps year year basis operate margin be expand bps year year basis oncology gross margin be bps particle therapy gross margin be quarter due mix lower margin deal financial company exit first quarter cash cash equivalent debt moreover cash flow operation be fy company expect revenue range adjust earning share be expect band cash flow operation be project range takevarian medical exit first quarter fiscal impressive performance rebound dismal performance last quarter solid revenue segmental support buoy optimism further expand foothold global market space be likely leverage company technical expertise however decline revenue proton therapy cutthroat competition niche space be concern price performanceover last month varian medical stock have be perform broader industry zack rank key picksvarian medical currently carry zack rank sell few better rank medical stock broader medical space be bio rad laboratory bio free report centene cnc free report bioverativ stock sport zack rank strong buy see complete list today zack rank stock here bio rad have estimate growth rate next quarter have positve average earning surprise trail quarters centene have long term expect growth rate have positve average earning surprise trail quarters bioverativ have project long term growth rate have positve average earning surprise trail quarters today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
136,VAR,be sign respite ongoing market uncertainty due apprehension trade war hand asian stock have start revive improvement north korea relationship other hand investor be restrain possibility trade loss due propose china trade restriction medical device catch trade war stormgoing datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total billionin medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade medtech trade group advame make more specific comment claim chinese tariff account more half medtech import region massdevice article trade group state industry propose additional tariff import nearly bn medical technology product be wrong action wrong time advame counter unite state trade representative ustr claim china unfair trade practice medical device harm export significantly group argue trade china medical device ustr list be fact slight surplus accordingly propose tariff diagnostic product other medical device make unite state china be not drop result trade imbalance rbc capital market estimate propose tariff get implement cost medical device industry year go latest update financial express report bipartisan group lawmaker have urge trade representative robert lighthizer remove worth medical device list chinese product propose trump administration additional tariff investor trouble risk trade war largest economy heighten investment medical device stock be take backseat propose imposition additional tariff chinese product china retaliatory effort have result widespread share loss so far medical device sector bearish emerge market trade outlook have dealt severe blow bigwig note sector have gain significantly profit earn number medical device company bric nation regard note stock medtronic plc mdt free report ge healthcare ge free report other be witness considerable weakness mar talk china trade war start do round note medtronic earlier buy orthopedic device maker china kanghui holding then have be consistently shipping product unite state operation shipment be now subject additional tariff definitely hamper company china business ge healthcare have also urge administration remove certain part list chinese product additional tariff go mass device report china produce part be essential number ge device include ultrasound machine patient monitor mri machine ct machine ray machine be produce ge own facility china other be produce local chinese company medtech stock counter trade restriction hazardconcern implementation trade tariff medtech product have be weigh stock lately even market have not yet show steady plunge such fear be likely dampen investor sentiment go forward have shortlist medtech stock spite tumultuous market condition be well poise strong fundamental timely strategic development selection be also backed good zack growth score zack rank have narrow choice help new style score system research show stock growth score combine zack rank strong buy buy offer best investment opportunity value investing space see complete list today zack rank stock here baxter international inc bax free report company have strong presence overseas market have such business relation china hence spite consider international diversification core component company strategy company very well sidestep volatility china trade war continue enjoy bountiful scope offer emerge market company fact be benefit develop country incremental investment health care system baxter have growth score zack rank company have impressive long term expect growth rate higher industry varian medical system inc var free report second quarter fiscal varian medical global market share growth be drive order base share gain emea fact varian medical be award contract truebeam system stockholm sweden further company sign agreement acquire australia base sirtex focuse interventional oncology therapy apart varian medical have recently announce open new facility jundia brazil extend global manufacturing training footprint region varian medical have business greater china company huge global base outside country shield severe damage occur result trade restriction varian medical have growth score zack rank abiom inc abmd free report just baxter have strong international foothold abiom do not have significant presence china fourth quarter fiscal germany japan witness strong adoption exclusive impella product line germany revenue grow fourth quarter fiscal japan abiom exceed expectation expect add revenue fiscal abiom have growth score zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
137,VAR,have be pay attention share baxter international bax free report share have be move stock past month bax hit new week high previous session baxter international have gain start year compare move medical sector year date return peer group drive outperformance stock have impressive record positive earning surprise have beaten zack consensus estimate last quarters last earning report april baxter international report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year baxter international be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricsbaxter international be week high right now future hold bax key aspect question be take look valuation metric order determine company have run ahead front look zack style score provide investor additional way sort stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style baxter international have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective baxter international inc price consensus baxter international inc price consensus baxter international inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately baxter international currently have zack rank buy thank favorable earning estimate revision cover analyst recommend investor select stock carry zack rank strong buy style score look baxter international meet list requirement thus seem bax share have potential week month come do baxter international stack competition share baxter international have be move higher company still appear be decent choice rest industry industry peer be also look good include biolife solution blfs free report surmodic srdx free report varian medical system var free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news baxter international still fundamental bax be promising still have potential be week high
138,VAR,varian medical system inc var free report recently launch velocity new version flagship velocity cancer imaging platform system enhance patient specific imaging radiation dosimetry target cancer therapy velocity be design patient liver malignancy include rapidsphere module selective internal radiation therapy sirt dosimetry analysis believe varian medical strategy target radiation dosimetry market be timely consider higher profit niche space report business wire global market radiation dosimeter be project witness cagr notably velocity rapidsphere module have receive clearance fda earlier share upvarian medical share have rally follow announcement close fact zack rank hold company outperformed industry year time precisely stock have return compare favorably industry rally also current return be higher index gain varian medical velocity unit drive growthvarian medical velocity platform be major contributor revenue grow strong double digit first quarter fiscal velocity oncology imaging informatic system be vendor neutral software solution collect integrate oncology datum pertain medical imaging treatment metadata help patient ready datum access system allow clinician measure change time enable tumor delineation evaluate cancer treatment used medical imaging datum inclusion rapidsphere software velocity now provide ability cancer care team study tumor response normal tissue toxicity individual patient receive sirt market prospect brightwhile latest development focuss specifically liver cancer space varian medical have be global leader develop deliver cancer care solution type research report mordor intelligence project global liver cancer therapeutic market be expect register cagr however aggressive rivalry niche market be headwind varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer accuray key picksa few better rank player broader medical sector be bio rad laboratory bio free report abaxis inc abax free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate abaxis zack rank buy stock have long term earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
139,VAR,varian medical system inc var free report be prospective name global medtech space stock have return compare favorably industry gain year time also current return be higher index rally market capitalization approximately stock have meet earning expectation past trail quarters however company have be grapple few issue moment cutthroat competition persistent softness market freestand clinic be likely hamper company prospect thank somewhat mixed trend stock have zack rank hold here take detailed look company performance operation analyze investor hold stock favore varian medical varian medical impressive performance oncology business improve margin launch halcyon radiotherapy treatment system be key highlight moment favorable revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country well new partnership deal be positive company have be strong player latin america varian medical announce open new facility jundia brazil extend global manufacturing training footprint region partnership brazilian ministry health varian medical aim bring greater access advanced radiotherapy treatment country greater latin america believe brazil base facility provide access advanced radiotherapy treatment latin america regard research report market datum forecast show radiotherapy market latin america be worth be estimate witness cagr reach consider bountiful prospect varian medical be likely grow manifold leverage oncology segment estimate international agency research cancer world health organization annual cancer rate world be project increase believe higher demand varian medical product china india brazil continue drive international revenue long run company expect revenue range adjust earning share be expect band cash flow operation be project range be probable headwind varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer elekta accuray emerge proton therapy market company face competition hitachi ion beam application mevion medical system sumitomo intense competition be anticipate increase expenditure nascent proton therapy market keep margin pressure moreover pricing pressure traditional radiotherapy be major concern further lackluster performance particle therapy segment have be concern revenue segment decline year year basis first quarter fiscal still hold unhindered persistent issue analyst be optimistic varian medical zack consensus estimate be peg share show increase last month current quarter zack consensus estimate be reflect rise varian medical system inc price consensus varian medical system inc price consensus varian medical system inc uptick be attribute varian medical product solution have be experience rapid adoption be evident company impressive top line performance first quarter revenue totale increase year year varian medical have vgm style score here stand value growth momentum notably vgm score be comprehensive tool help investor screen winning stock broader sector further score highlight determine element stock drive higher research show stock vgm score offer best upside potential varian medical system inc revenue ttm varian medical system inc revenue ttm varian medical system inc quotein investor want hold stock courtesy prospect outperform peer future temporary sluggishness company have be successful front be evident year year expansion top line believe varian medical innovative product pipeline continue drive overall growth long term key picksa few better rank player broader medical sector be bio rad laboratory bio free report abaxis inc abax free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate abaxis inc abax free report zack rank buy stock have long term earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
140,VAR,mar issue update research report athenahealth inc athn free report company strong product portfolio solid network expansion strategy unique business model be tailwind consequently athenahealth be top perform stock medtech sector stock sport zack rank strong buy further improvement share price strong fundamental indicate analyst bullish sentiment price performance estimate revision trend estimate athenahealth have moved upward past day reflect analyst optimism stock zack consensus estimate earning have be revise upward respectively share company have outperformed industry year time stock have return compare industry rally athenahealth inc price consensus athenahealth inc price consensus athenahealth inc quote let focus factor make athenahealth attractive pick investor favorable portfolio comprise wide array product include electronic health record revenue cycle management medical bill patient engagement care coordination population health management epocrate end fourth quarter athenahealth launch first machine learn model automate faxe company also pilot service authorization management be likely expand client base athenainsight online news hub report healthcare activity trend healthcare provider identify patient have be fortify company footprint athenahealth expand patient record sharing capability commonwell carequality full year company expect adjust operate margin range company have not provide guidance adjust earning athenahealth estimate total revenue range other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report perkinelmer pki free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy perkinelmer have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
141,VAR,varian var free report recently announce receipt anvisa registration halcyonsystem brazil registration varian now be able market system country treatment used halcyon platform be cost effective short duration also enhance patient comfort system have be ergonomically design provide user friendly platform clinical staff patient company also state system help accelerate complex image guide imrt plan compare traditional device halcyon treat majority cancer patient offer advanced treatment prostate breast head neck many other form disease notably platform receive order last report fourth quarter order be emea north africa apac development oncologyvarian be consistently try boost oncology segment regard company have initiate first education workshop radiotherapy practitioner algerium further company recently announce first cancer patient be treat used hyperarc high definition radiotherapy hdrt new type radiosurgery treatment sacro cuore don calabrium cancer care center negrar verona italy notably revenue be cer segment fourth quarter late company have be focuse expansion brazil regard varian recently announce plan open new facility jundiai brazil reflect long term commitment partnership brazilian ministry health facility have be fully equip provide varian trilogy linear accelerator hand training physician growth halcyonrecently halcyon platform receive clearance ce mark european directive allow varian start selling system unite state europe also november company announce receipt shonin approval ministry health labor welfare mhlw market halcyon japan company strong overseas presence be expect enable cash opportunity emerge market market prospectsaccord report market market global radiotherapy market be project reach worth cagr look bountiful opportunity niche space believe company latest development be strategic fit stock performance solidover past month varian have outperformed broader industry term price company have return compare favorably sub industry gain just zack rank key picksvarian carry zack rank sell few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology andmyriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year time wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
142,VAR,edward lifescience corporation ew free report have announce compute tomography imaging partner trial sapien valve sub study have recently complete enrollment notably sub study be evaluate leaflet mobility sapien surgical heart valf patient be low risk experience valve replacement treat severe aortic stenosis datum main partner study be present acc notably company expect fda approval indication late management edward lifescience be study sapien ultra system feature balloon delivery system next generation sheath technology part single arm multus center trial intermediate risk patient company now anticipate system launch late europe unite state also announce update timing european launch system do not change sale guidance peg high end project range market potentialper report market research global heart valve device market be estimate be worth end cagr very noteworthy player niche be abbott free report thv focusbasically sapien be artificial valve fall edward lifescience transcatheter heart valf thv segment thv segment include technology design treat heart valve disease used catheter base approach opposed open surgical technique fourth quarter company report thv sale growth prior year quarter tally unite state thv increase year year attributable excellent clinical performance sapien well continue strong therapy implementation region outside unite state underlie growth rate be contribution region company continue see strong tavr therapy adoption japan drive sapien buoy previous quarter strong performance edward lifescience now predict full year thv sale growth rate high end guide range also management thv boast highest margin business late edward lifescience have witness multiple development thv segment good news be company have recently receive ce mark self expand centera also management release positive patient outcome sapien valve include high survival rate low rate stroke paravalvular leak share price estimate revision trendedward have be gain investor confidence consistently positive result year time company share price have outperformed industry stock have soar compare industry rally headquarter irvine company estimate revision trend have be positive past couple month analyst moved north revision opposite direction earning estimate rise share zack rank other key picksedward lifescience carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
143,VAR,fortify extremity fixation portfolio orthofix international ofix free report recently announce receipt fda clearance beam fusion beam system be line company strategy gain traction charcot diabetic foot market segment beam system internal fixation system aids treat charcot foot condition beam device provide proper alignment fixation stabilization implanted medial lateral column foot hence reduce chance amputation management leverage exist product line truelok tl hex fda approval beam device boost internal fixation segment charcot foot treatment well top line contribution extremity fixation sbu extremity fixation sbu glanceorthofix extremity fixation strategic business unit sbu manufacture distribute orthopedic product treat fracture deformity correction repair bone reconstruction condition company continue witness impressive top line contribution unit segment account total net sale strength pediatric foot ankle strategic product area solid performance business unite state drive segment performance furthermore management believe improve instrument set inventory management spine extremity fixation sbu expand company gross margin market potentialper company severe neuropathy nerve damage cause charcot foot moreover be common diabetic foot complication many diabetic patient suffering condition study diabetic patient neuropathic patient have be report condition encouragingly note number patient age year diagnosed diabetes be expect rise international diabetes foundation view datum believe fda approval have come opportune time company cash bountiful opportunity niche market price performanceover past month orthofix share have outperformed industry belong stock have gain compare industry rise zack rank key picksorthofix carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
144,VAR,idexx laboratory inc idxx free report have be gain investor confidence consistently positive result stock have surge year ahead gain broader industry rally moreover company have market cap year historical growth rate be also favorable compare industry dwelling solid prospect zack rank buy stock be attractive bet investor moment company estimate revision trend have be positive last day analyst revise estimate upward movement opposite direction consensus mark earning increase share style score idexx laboratory sport growth score reflective company strong fundamental research show stock impressive growth style score combine favorable zack rank strong buy offer best upside potential idexx laboratory inc price idexx laboratory inc price idexx laboratory inc quote regard idexx laboratory have favorable net margin net income sale industry negative also company sale asset ratio compare industry signify sturdy growth pick let find recent positive momentum be sustainable company be lead manufacturer product service primarily companion animal veterinary livestock poultry exit fourth quarter promising note stable year year growth organic revenue be also encourage stock stellar performance be drive robust sale cag companion animal group business fourth quarter cag organic revenue rise low double digit back strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth additionally be upbeat company expand premium instrument base unite state international market include improve competitive instrument placement increase utilization continue customer retention regard be also optimistic gain commercial launch catalyst sdma test north america january breakthrough company point care customer be able add sdma essential element routine chemistry panel continue slew development idexx laboratory enter global agreement january diagnostic company apply biocode agreement idexx laboratory bring reference laboratory customer digital multiplex platform build apply biocode management aim commercially launch technology companion animal market fundamental remain consolidated tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover substantial top line growth quarter be drive considerable contribution other business segment furthermore raise guidance earning share instill confidence stock be also upbeat company witness double digit organic revenue growth international business upside reflect consistent consumable revenue gain support catalyst instrument base average testing utilization additionally company have secure cash balance allow carry share repurchase meanwhile idexx laboratory heavy reliance third party distributor raise concern moreover tough competitive landscape domestic overseas market weigh company margin other key pickssome other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
145,VAR,lead way grow market urology boston scientific corporation bsx free report have recently enter agreement buy minnesota base nxthera deal value privately hold nxthera be developer marketer rezum system unite state europe transaction be expect complete second quarter subject customary close condition financial term transaction consist upfront payment cash additional potential commercial milestone payment next year notably company have exist minority investment nxthera expect result net upfront payment approximately close milestone fee nearly nxthera rezum bph strategic deal bsx patient symptom arise benign prostatic hyperplasia bph rezum system nxthera come minimally invasive therapy option bph cancerous prostate gland enlargement be quite common age male create attractive market disease affect man worldwide more symptomatic man alone unite state be undergo treatment condition medication procedural approach notably bph cause symptom affect patient qualify life such pain frequent need urinate many positive rezum system nxthera be impressed hassle free procedure be perform physician clinic general anesthesia thereby reduce cost bph therapy core moreover treatment apply water vapor remove excess prostate tissue alleviate obstruction urine flow further help mitigate bph related symptom also prevent unwanted side effect come intake maintenance medication control bph boston scientific mentioned favorable clinical study related rezum system management state study publish march issue journal urology demonstrated year period patient treat rezum system have clinical progression rate be time lower report rate patient treat daily long term medication additional clinical datum randomize controlled trial demonstrated patient treat rezum system have reduction symptom month post treatment maintain percent reduction bph symptom year post treatment project synergy dealpost deal closure buyout nxthera be expect remain immaterial boston scientific adjust earning share ep be only accretive afterwards consolidation be likely be dilutive less beneficial report basis due amortization transaction integration cost reckon boston scientific urology pelvic health arm be highest operate margin business company acquisition am urology portfolio have burgeon urology business size almost double value significantly urology represent attractive global market potential large unmet patient need considerable international expansion opportunity believe nxthera buyout post completion enable company capitalize opportunity share price performance boston scientific have be gain investor confidence consistently positive result last month share company have outperformed broader industry stock have rally compare industry gain zack rank key picksboston scientific carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
146,VAR,baxter international inc bax free report have complete acquisition hemostat sealant product mallinckrodt plc widen exist surgical portfolio hemostat sealant especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter expect deal be modestly accretive adjust earning thereafter transaction deal increasingly add capability baxter portfolio drive bottom line turn deal be buy preveleak upfront payment approximately potential contingent payment future deal be announce earlier january baxter now gain major traction only stand alone recombinant thrombin buyout provide more option innovative hemostatic product surgeon deal severity bleed preveleak used vascular reconstruction complement company exist portfolio advanced surgical sealant baxter surgical portfoliobaxter surgical portfolio include product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other portfolio be compose hemostasis address bleed tissue sealing hard tissue regeneration well soft tissue repair microsurgery product available nearly country company consistently endeavor improve advanced surgery business company expect advanced surgery business increase constant currency basis baxter have also announce plan focus launch advanced surgery product japan come day market potentialper cision report global surgical medical device market be anticipate witness cagr forecast period reach worth consider bullish market sentiment think latest development be timely lead player niche space be abbott free report stock performance estimate revisionshare baxter have outperformed industry past year stock have rally outperform gain broader industry rise company estimate revision trend current year have be positive past couple month analyst moved north revision opposite direction earning estimate rise zack rank other key picksbaxter carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
147,VAR,varian medical var free report recently announce partnership penn medicine develop launch comprehensive proton therapy training education program management varian confirm training online course be available january latest development be likely enhance knowledge skill clinician therapist global proton therapy space fact continue education training be likely boost availability proton therapy product niche market proton therapy space glanceproton therapy proton beam therapy be type particle therapy used beam proton treat diseased tissue most often case cancer research report cision pr newswire suggest global proton therapy system market be expect reach favorable reimbursement policy unite state europe rise awareness cancer related healthcare policy expenditure emerge nation be likely propel proton therapy space long haul fact various report suggest proton therapy space be dominate unite state thank massive investment development therapy center now come lead player space hitachi ion beam application mevion medical system sumitomo also deserve mention meanwhile proton therapy market be grow manifold expect witness stellar demand come day varian strong footholdapart enjoy dominant market share conventional radiotherapy believe proton therapy also hold significant promise varian be company flagship probeam compact proton therapy system be superior other external beam radiotherapy available market probeam precisely locate cancerous tumor thereby cause lesser side effect surround tissue regard varian proton therapy portfolio have product probeam proton therapy system probeam compact single room proton therapy solution probeam multus room proton therapy solution however company have see lackluster performance proton therapy segment recently last quarter revenue segment be year year basis quarter varian book order include concord medical proton center guangzhou china hcg india yet proton therapy order grow same period year year basis believe such development help varian gain traction niche space share shine brightover past month varian outperformed broader industry term price performance company return compare favorably broader industry gain just also current return be higher gain same time frame zack rank stock considervarian have zack rank sell few other top rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
148,VAR,varian medical system var free report recently announce plan open new facility jundiai brazil reflect long term commitment partnership brazilian ministry health facility have be fully equip provide varian trilogy linear accelerator hand training physician notably manufacturing warehousing area facility be expect be operational end latest development closely follow receipt shonin approval japan ministry health labor welfare market varian halcyon system exclusive platform cancer treatment image guide volumetric intensity modulate radiotherapy varian have be continuously focuse boost global education training department latest facility be locate multivias industrial park have demonstration room training classroom management varian expect provide training clinician therapist use radiotherapy equipment treatment plan technique global growth focuswe believe facility provide access advanced radiotherapy treatment latin america particularly brazilian oncology market regard research report market datum forecast show radiotherapy market latin america be worth be estimate see cagr reach consider bountiful prospect varian be likely grow manifold leverage oncology segment notably varian receive regulatory clearance market halcyon unite state europe recently italy company recently announce initiation treatment used hyperarc high definition radiotherapy hdrt new type radiosurgery treatment sacro cuore don calabrium cancer care center negrar verona algerium varian conduct day workshop radiotherapy practitioner september varian have system operate algerium moment company strong overseas presence be expect enable cash opportunity emerge market share price move upover past month varian have outperformed broader industry term price company have return compare favorably sub industry gain just also current return be higher gain takevarian expand international presence be likely be only factor boost investor sentiment give company lackluster result just report fourth quarter fiscal fact company oncology gross order decline year year constant currency apac region believe varian recent initiative boost presence latin america lead growth apac region however varian compete large electronic company well smaller more specialize radiation therapy equipment manufacturer accuray incorporate aray free report bard inc thus cutthroat competition niche space be likely impede company sale growth zack rank key pickvarian have zack rank sell better rank stock broader medical sector be petm express pet free report zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
149,VAR,varian medical system var free report announce receipt shonin approval ministry health labor welfare mhlw market varian halcyon system new system design cancer treatment simplify improve almost aspect image guide volumetric intensity modulate radiotherapy imrt notably platform receive clearance ce mark european directive allow varian start selling system unite state europe company unveil halcyon radiotherapy treatment system astro conference vienna third quarter notably treatment used halcyon platform be cost effective short duration well enhance patient comfort system have be ergonomically design provide user friendly platform clinical staff patient company also state system help accelerate complex image guide imrt plan compare traditional device halcyon treat majority cancer patient offer advanced treatment prostate breast head neck many other form disease notably platform receive order last report fourth quarter order be emea order north africa apac varian medical be consistently try boost oncology segment regard company have initiate first education workshop radiotherapy practitioner algerium further company recently announce first cancer patient be treat used hyperarc high definition radiotherapy hdrt new type radiosurgery treatment sacro cuore don calabrium cancer care center negrar verona italy notably revenue be cer segment fourth quarter accord report market market global radiotherapy market be project reach worth cagr look bountiful opportunity niche space believe company latest development be strategic fit past month varian medical have outperformed broader industry term price performance company have return compare favorably sub industry gain just zack rank key picksvarian medical carry zack rank sell few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology myriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
150,VAR,varian medical system inc var free report report adjust earning share fourth quarter fiscal miss zack consensus estimate adjust earning also decline year year basis meanwhile revenue be year quarter revenue miss zack consensus estimate narrow margin varian medical end year backlog year year basis unfavorable performance company proton therapy unit be primary cause lackluster fourth quarter performance however solid guidance fiscal instill confidence stock palo alto base manufacturer medical device software carry zack rank hold varian medical system inc price consensus ep surprise varian medical system inc price consensus ep surprise varian medical system inc quotesegment detailsoncology system segment revenue totale year year constant currency cc oncology growth be drive double digit service growth newly issue upgrade hardware software notably varian medical register order hyperarc platform fourth quarter hyperarc be recently launch high definition radiotherapy technology gross order segment totale cc year quarter unite state gross order increase cc emea region gross order rise year year basis courtesy solid growth france germany poland india flipside gross order decline cc apac region thank weakness japan proton therapy fourth quarter revenue segment be year year basis quarter varian medical book order include concord medical proton center guangzhou china hcg india proton therapy order growth be year year basis halcyon drife growthvarian medical have be take initiative gain customer attention broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna last quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform have order fourth quarter order be emea order north africa apac marginsin fourth quarter gross margin contract basis point bps revenue oncology system gross margin contract nearly bps owing supply chain inefficiency percentage revenue expense research development remain flat year year basis meanwhile selling general administrative sg expense quarter be bps year year basis operate margin quarter review be net revenue bps year year notably fourth quarter last year include favorable bad debt release addition investment varian medical have spend capex buy back share company stock end fourth quarter varian medical have share remain exist repurchase authorization fy fiscal varian medical register adjust earning share revenue be cc year oncology revenue be cc full year revenue proton therapy unit totale year year company book proton therapy order fiscal fiscal be favorable varian medical term product launch well successful launch halcyon therapy system hyperarc technology deserve mention regard fy fiscal management estimate adjust earning share range cash flow operation be project fiscal revenue be estimate grow year year company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock carry zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
151,VAR,third quarter earning season have commence encourage note most sector release participant total market cap october latest earning preview total earning member rise higher revenue member line release quarterly result week be decidedly bullish equity market be gradually demonstrate sequential improvement medical broader sector zack sector be expect put impressive show quarter expect earning growth rate sector be revenue growth comparison report earning growth rate second quarter be quite impressive revenue growth medical product political medical product space broader medical universe have be precarious game republican day courtesy president trump repeat failure repeal replace obamacare however major medtech player have be pin hope abolition infamous medical device sale tax elimination tax be far be achieve consider tax issue investor interested medical product space likely keenly await earning report medtech bigwig baxter international inc bax free report varian medical var free report thermo fisher scientific inc tmo free report laboratory corporation america holding lh free report notably company be expect release earning result oct third quarter baxter anticipate sale growth constant currency cc adjust earning share be forecast range cent versus year figure cent believe company solid sale medical product segment be key driver third quarter notably zack consensus estimate segment stand year year basis read more baxter international earning store solid prospect quantitative model do not conclusively show beat company give combination zack rank buy earning esp be model stock need have positive earning esp zack rank strong buy hold beat earning baxter international inc price consensus baxter international inc price consensus baxter international inc quotewe be upbeat varian medical oncology business be estimate account company total revenue fourth quarter fiscal company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space fourth quarter fiscal varian expect adjust earning share range revenue be likely increase year year basis read more varian medical earning be surprise store contrary zack consensus estimate varian medical revenue stand year year consensus estimate earning be peg year year proven model do not predict earning beat company season thank earning esp zack rank see complete list today zack rank stock here varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotelaboratory corporation also know labcorp continue face softness covance drug development business third quarter however be upbeat company expectation improvement covance drug development arm start second half be reflect third quarter performance read more card labcorp earning season zack consensus estimate labcorp third quarter revenue stand year year labcorp be concern cms center medicare medicaid service proposal related protect access medicare act pama believe reimbursement pressure affect company performance third quarter well fact proven model do not predict earning beat company season be labcorp have zack rank earning esp uncover best stock buy sell re report earning esp filter laboratory corporation america holding price consensus laboratory corporation america holding price consensus laboratory corporation america holding quotethermo fisher be gear solid third quarter result primarily drive analytical instrument segmental growth third quarter company expect see positive impact electron microscopy business well strong volume leverage productivity zack consensus estimate analytical instrument operate income be peg line last quarter report number total revenue estimate segment be impressive level read more expect thermo fisher earning quantitative model predict earning beat thermo fisher stock currently have zack rank earning esp zack consensus estimate revenue be third quarter year year basis thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus thermo fisher scientific inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
152,VAR,boston scientific corporation bsx free report recently present favorable real world datum true hd study annual congress european heart rhythm association ehra latest move be line company strategy gain traction global ep market be poise reach value datum market market study result observational prospective randomize study true hd study cover patient suitable cardiac mapping ablation treat arrhythmia however patient diagnosed atrial fibrillation be not enrolled study notably true hd study evaluate procedural process acute success safety mapping ablation various clinical arrhythmia company study result display safety efficacy rhythmia mapping system used intellamap orion mapping catheter mapping support treatment different type arrhythmia also include case ablation atrial fibrillation base other technique be failure rhythmia mapping systemis catheter base cardiac mapping navigation solution help diagnose treat different type arrhythmia glimpse ep businessboston scientific ep business develop less invasive medical technology diagnose treat disorder heart rate rhythm revenue division fourth quarter improve year year cer upside be drive higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently launch unite state well japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system additionally focus add tool expand reach utility rhythmia hdx different procedure regard boston scientific expect full fledge directsense technology europe unite state follow successful initial launch europe moreover order expand ep business boston scientific acquire apama medical inc october company also intend integrate rhythmia hdx mapping system apama rf balloon system improve visualization heart ablation process market potentialboston scientific strategy boost ep business seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise age population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market be anticipate witness cagr space market be expect witness highest momentum cagr share price scientific have be gain investor confidence consistently positive result last month share company have outperformed broader industry stock have rally compare industry gain zack rank key picksboston scientific carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
153,VAR,mar issue update research report medical group wmgi free report medical carry zack rank hold company be focuse strategic acquisition divestiture however foreign currency fluctuation remain woe company recently complete acquisition imascap sas leader development software base solution preoperative plan shoulder replacement surgery management be also quite optimistic recent acquisition blueprint also medical decision sell orthorecon unit microport medical subsidiary microport scientific corp bode well company company recently report fourth quarter result adjust earning revenue surpass respective zack consensus estimate company witness growth business segment also expansion gross margin buoy optimism medical be focuse product innovation research development company recently launch invision total ankle revision system first system develop total ankle revision arthroplasty medical derive significant part total revenue international operation be be adversely affected fluctuation foreign currency exchange rate strong dollar be dent company international revenue subsequently putt pressure gross margin also lackluster international performance lower extremity segment be raise concern also pricing pressure continue trouble medical increase cost related product launch re build infrastructure be expect put pressure margin problem associate distributor be major headwind past month medical have underperform industry company share have lose industry rally almost key picksa few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
154,VAR,medtronic plc mdt free report announce positive result analysis conduct adaptivcrt algorithm european heart rhythm association ehra scientific session barcelona spain study demonstrated adaptivcrt algorithm reduce atrial fibrillation af episode higher patient activity level result be base heart failure patient medtronic cardiac therapy crt device center italy first study show significant reduction occurrence af episode measure duration patient adaptivcrt compare patient traditional crt second study reveal adaptivcrt be link higher daily activity level patient feature compare patient conventional crt company crt be establish treatment patient heart failure use implantable defibrillator crt pacemaker crt enhance heart pump efficiency adaptivcrt platform glancein medicine crt resynchronize contraction heart ventricle send electrical impulse heart muscle thus crt help heart pump blood body more efficiently be very promising technique market cardiac rhythm management heart failure medtronic adaptivcrt platform minutely evaluate cardiac rhythm back pace operation namely adaptive lv adaptive major crt platform medtronic clarium mri crt percepta crt mri deserve mention development cardiac rhythm heart failure company be consistently try improve cardiac rhythm heart failure division part cardiac vascular group cvg line medtronic recently announce receipt fda approval commercial launch portfolio azure pacemaker bluesync technology medtronic receive fda approval quadripolar cardiac therapy pacemaker crt ps improve therapy delivery patient heart failure market potentialper globaldata report global heart failure market be set reach worth cagr consider bullish market sentiment believe latest development be timely stock performance estimate revisionover past month share medtronic have underperform industry stock have dip industry index gain also estimate revision trend current year be unfavorable estimate move south last month compare opposite direction earning estimate fall share zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
155,VAR,varian medical system inc var free report be schedule report fourth quarter fiscal earning oct market close last quarter company deliver earning share beat zack consensus estimate cent however adjust earning decline year period factor playwe be upbeat varian medical oncology business account company total revenue fourth quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space fourth quarter varian expect adjust earning share range revenue be expect increase year year basis company recently launch fda approve product halcyon strengthen foothold oncology business varian medical also sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open office africa middle east depict be aware opportunity region moreover varian medical strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quotestock considerhere be company consider model show have right combination element post earning beat upcoming quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
156,VAR,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report announce have initiate treatment latest halcyon radiotherapy treatment system europe notably treatment be provide year old male head neck cancer belgium base university hospital leuven uz leuven just month hospital have order new system halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform receive clearance ce mark european directive allow varian start selling system unite state europe company unveil halcyon radiotherapy treatment system astro conference vienna third quarter notably treatment used halcyon platform be cost effective short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon fortify varian global footholdvarian have long term goal treat cancer patient year highly exclusive radiotherapy treatment end third quarter management varian announce halcyon have receive order country north america varian strike strategic deal petcure deliver halcyon unit veterinary oncology network management regulatory clearance china japan follow next year furthermore varian receive order halcyon system icon group australia company book several order country india morocco romania russia turkey market prospectsvarian have be take initiative gain customer broad spectrum product especially target emerge market strong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian datum market market reveal global radiotherapy market be project reach worth cagr other company eyee emerge marketsthe ongoing political uncertainty unite state deteriorate economic condition europe automatically shift focus several medtech player emerge geography china india latin america other johnson johnson jnj free report have set manufacturing center brazil china india have be do business china nearly year be expand further back synthe acquisition thermo fisher tmo free report be also leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strong growth country colombia mexico peru argentina today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
